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Abstract 
Aims 
The aim of this study was to undertake a micro-costing approach to determine the 
secondary care costs to the National Health Service (NHS) associated with the cleft care 
pathway of patients being treated from birth until 10 years of age for bilateral cleft lip and 
palate (BCLP), cleft palate only (CPO) and unilateral cleft lip and palate (UCLP). This was 
compared to NHS reference and tariff costs. 
Methods 
A care pathway was mapped out for a child born with BCLP, CPO and UCLP. 23 case notes of 
children born with orofacial clefting were identified. Retrospective data collection of 
episodes of care were recorded. Costs of care were calculated using local and national 
sources in order to compare against NHS reference and tariff costs. 
Results 
Mean costs for BCLP, CPO and UCLP were £17,004.09 (SD £7,361.83), costs £6,137.49 (SD 
£2,319.87) and £11,619.74 (SD £2,547.81) respectively. Costs in BCLP were the highest due 
to the increased surgical care required when compared with CPO and UCLP. CPO had the 
lowest mean cost due to the least surgical care required. Did not attend (DNA) rates were 
similar in each of the phenotypes ranging from 5% and 8% of total appointments missed. 
Conclusion 
Costs for provision of care for BCLP, CPO and UCLP from birth to 10 years of age are 
significant and can vary based on the surgical and outpatient care provided. Staff costs 
formed the largest proportion of costs identified. 
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ABG   Alveolar bone grafting 
BCLP   Bilateral cleft lip and palate 
BNF   British National Formulary 
CLP   Cleft lip and palate 
CP   Cleft palate 
CPO   Cleft palate only 
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CSA   Certified surgical assistant 
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OMFS   Oral and Maxillofacial Surgery 
PPE   Personal protective equipment 
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Orofacial clefting is the most common craniofacial congenital condition found in humans 
(Slator et al., 2009) and presents in two main forms: cleft lip (with or without palatal 
clefting), or cleft palate (without lip clefting). Cleft lip and palate (CLP) is more common and 
is seen in 1-2 per 1000 live births. Cleft palate (CP) or cleft palate only (CPO) is seen in 1 per 
1500-2000 live births. These relatively common congenital conditions are frequently 
associated with one of more than 400 distinct syndromes. This association is seen in 
approximately 30% of CLP affected children and 50% of CP affected children (Lidral et al., 
2008).  
The care for cleft affected children involves a multidisciplinary approach with numerous 
interventions, often over a 20-year time period. A team approach involving nurse specialists, 
speech and language therapists, orthodontists, paediatric dentists, audiologists, Ear Nose 
and Throat (ENT), Plastic and Oral and Maxillofacial Surgery (OMFS) is required (Slator et al., 
2009).  
The protracted nature of the treatment in terms of time, travel and number of 
appointments can be challenging for the child and their family in relation to the 
commitment that is required. In addition to this, the costs to the NHS are not 
inconsiderable. To date, there is no comprehensive assessment of the estimated costs 
associated with treatment of orofacial cleft affected individuals. Health economics models 
provide information to aid decision-makers in allocating resources where there is a finite 
quantity available. This requires clinicians and healthcare policy makers to prioritise 
healthcare needs, determining which care can, or cannot, be met due to financial 
constraints (Morris et al., 2012). It is therefore important to evaluate the cost of cleft care 
to the NHS to improve budget allocation. Determining the costs could potentially allow a 
protected monetary reserve to be allocated to facilitate better quality care, by ensuring that 
departments are appropriately remunerated for the provision of care to cleft affected 
individuals. An economic evaluation would allow the cost of treatment to be weighed up 
against the perceived benefits (Drummond, 2015). At present, this is not possible as the true 
cost of cleft care is unknown. 
2. Literature Review 
 
2.1 Orofacial Clefting 
 
2.1.1 Embryology of clefts 
 
Clefting of the lip and/ or palate occurs when there is incomplete development or union of 
the orofacial structures in utero. In order to understand how clefts arise, and the likely 
problems and treatments an affected individual will encounter, normal orofacial 
development is described.  
The cranial aspect of the embryo in humans develops relatively early on, with differentiation 
of cells beginning at around 20 days to form the neural systems. The three germ layers that 
initially form are the ectoderm, mesoderm and the endoderm, and it is these cells that 
differentiate to form the different types of cells and components required for development. 
The ectoderm eventually forms neural crest cells, which go on to make contact with the 
pharyngeal endoderm and mesoderm by the fourth week in utero, producing the five facial 
prominences: 
• The frontonasal process 
• The paired maxillary processes 
• The paired mandibular processes 
Towards the end of the 5th week of development the palate begins to form and is complete 
by week 12. The primary palate forms as a result of the medial nasal prominences fusing 
with the maxillary processes.  It contains the maxillary incisors as well as forming the 
anterior hard palate and alveolar arch anterior to the incisive foramen. Secondary palate 
formation begins during the 6th week of development. The paired maxillary processes grow 
vertically down alongside the tongue bilaterally. As the tongue drops inferiorly during week 
7, the palatal shelves migrate and sit horizontally above the tongue. The secondary palate 
fuses initially anteriorly and progresses posteriorly to completion at the uvular.  
Clefts can arise as a result of disruption at any of these stages of lip and palate formation, 
with the final presentation dependent on the location and timing. Cleft lip and or palate 
occurs as a result of failure of the union of the lateral or medial nasal process and, or the 
















Figure 1. Development of the upper lip and palate in the 5th week of embryological 
development (Smarius et al., 2017) 
 
2.1.2 Aetiology of clefts 
 
Cleft lip and palate is a condition that can present as an isolated disruption during palatal or 
lip development, or may be part of a syndrome involving a number of additional phenotypic 
features. Most clefts are non-syndromic, with 70% of CLP and 50% of CP being non-
syndromic and the remainder associated with one of over 400 different syndromes (Lidral et 
al., 2008; Dixon et al., 2011). In the UK, cleft lip and palate affects around 1 in 700 live 
births, and worldwide approximately “1.7 cases arise per 1000 liveborn babies, with ethnic 
and geographic variation” (Mossey et al., 2009).  
Cleft lip and palate is a polygenic condition where genetic risk factors combine with 
environmental exposures (Dixon et al., 2011). Several genes have been linked to orofacial 
clefting (Table 1), including MSX1 (Jezewski et al., 2003), interferon regulatory factor 6 
(Dixon et al., 2011), T-box transcription factor-22, poliovirus receptor-like-1, and P63 
(Stanier and Moore 2004).  
Table 1. The “key genes required for craniofacial morphogenesis” linked to CLP (Stanier and 
Moore 2004) 
 
Environmental factors have also been widely studied and several have been linked to the 
development of CLP, including: 
1. Smoking, for which there is thought to be a weak but significant increased likelihood of 
developing CLP, with an increased relative risk of 1.3 to 1.5 (Kohli and Kohli, 2012). Specific 
genes in the infant have been shown to interact with maternal cigarette smoking, including 
the glutathione s-transferase (GSTT1), which increases the risk of CLP by almost 5 times 
(OR=4.9) (Rooij et al.,2001) and the MSX1, which increases the risk of non-syndromic clefts 
by almost seven times (Beaty et al., 2002).  
Polarising signals Shh, Bmp2, Bmp4 and Bmp7, Wnt5a, Smad2-4 
Growth factors and receptors Egf, Egfr, Tgfa, Tgf1-3, Fgf1, Fgf8, Fgfr1, Fgfr2 
Transcription factors Ap2, Dlx1-6, Gli2-3, Hoxa2, Irf6, Lhx8, Pax9, Pitx1, Prx1, 
Msx1, Tbx1, Tbx22 
Cell adhesion molecules Pvrl1, Connexin43, E-cadherin 
Extracellular matrix Col2A1, Col11A1 and Col11A2, Mmp2, Mmp3, Mmp9, 
Mmp13, Timp1-3, Fibronectin 
2. Heavy maternal alcohol use has also been shown to increase the risk of developing a CLP 
by as much as 4.7 times (Munger et al., 1996). Low level alcohol consumption has not been 
shown to increase the risk of orofacial clefting (Natsume et al., 2000).  
3. The relationship between maternal folic acid intake and CLP is not fully understood but 
the risk of developing a cleft may be tripled if vitamin supplements (mainly folic acid and 
cobalamins) are not taken during early pregnancy (Shaw et al., 2002).  Although low level 
folic acid supplements are thought to have little or no preventative effect on the 
development of CLP (Ray et al., 2003), high daily doses (10mg/day) have been shown to 
reduce the risks by up to 65% (Kohli and Kohli, 2012). 
4. Steroids are another environmental factor that have been studied due to their 
widespread use. A number of studies on mice have shown an increased incidence of CLP if 
glucocorticosteroids are given to the pregnant females (Melnick et al., 1981). Another study 
investigated maternal corticosteroid use in humans and found increased risks in humans for 
non-syndromic CLP (Carmichael et al., 2007). Prednisone has been shown to increase the 
risk of CLP by as much as 3.4 times (Park-Wyllie et al., 2000), which corroborates with 
evidence from animal studies (Kohli and Kohli, 2012).  
5. Anticonvulsants have also been noted to increase the risk for congenital defects 
(Hernandez-Diaz et al., 2012) and include phenytoin/hydantoin, oxazolidinones, valproic 
acid and carbamazepine (Kohli and Kohli, 2012). 
In summary it is clear there are both genetic and environmental influences on orofacial 
clefting, with interactions that are complex.  The effects can be varied and are based on: 
• The presence or absence of specific genes  
• The type of environmental factors and concentration 
• The stage of pregnancy when an environmental exposure has occurred  
2.2 Classification of clefts   
 
A number of different cleft classification systems are available. In 1922, Davis and Ritchie 
noted that articles relating to cleft lip and palate used different terms to describe the same 
conditions and felt the “terminology (was) considerably confused” (Davis and Ritchie, 1992). 
They decided that a three-group system would allow easier categorisation and used the lip, 
the palate and the alveolus as the segregations of the conditions. The alveolar process was 
to be the dividing line for this categorisation. The groups described were: 
• Group I: Pre-alveolar process clefts (clefts that have lip involvement) – Further 
categorised as unilateral, bilateral, or median and either complete or incomplete. 
• Group II: Post alveolar process cleft (palatal involvement) - Further categorised as 
hard or soft palate involvement 
• Group III: Alveolar process cleft (alveolar process involvement) – Further categorised 
as unilateral, bilateral, or median and either complete or incomplete. 
This system was predicated on a boundary “the alveolar process forms the foundation for a 
surgical grouping” (Davis and Ritchie, 1992, Allori et al., 2017). The system was criticised as 
being based on a surgical perspective, which is not a definitive way of treating the condition. 
Anatomy would provide a universally acceptable way of classifying the condition, regardless 
of what surgical procedures were carried out in different parts of the world. 
Subsequently, Brophy in 1923 produced a classification involving 16 forms of cleft palate 
with or without lip involvement. This was seen to be impractical due to the complexity of 
the classification. In 1931, Veau simplified the classification system into 4 morphological 
forms: 
• I – Soft palate clefts 
• II – Soft and hard palate clefts, up to the incisive foramen 
• III - Soft and hard palate clefts unilaterally extending through the alveolus 
• IV - Soft and hard palate clefts bilaterally extending through the alveolus (Allori et al., 
2017) 
In 1942, Fogh-Andersen, a surgeon from Copenhagen published a new classification system 
in which he too adopted the incisive foramen as the division line for the different types of 
orofacial clefting. The groups were: 
• Unilateral or bilateral clefting of the lip 
• Cleft lip with cleft palate 
• A cleft palate with no lip involvement 
• Rare atypical clefts (for example midline clefting) (Allori et al., 2017) 
The classification developed by Kernahan and Stark in 1958 classified orofacial clefting in 
line with the embryological formation of the cleft, rather than being centred around 
potential surgical correction. With the demarcation between the primary and secondary 
palates being the incisive foramen, a failure of formation of the “primary palate” (from the 
incisive foramen and anterior to it) would cause clefting of the lip and alveolus within the 
first 7 weeks of intra-uterine life. A failure of formation of the “secondary palate” (the hard 
and soft palates) in the subsequent 5 weeks would lead to clefting posterior to the incisive 
foramen.  
Therefore, the new classification was as follows: 
• Clefts anterior to the incisive foramen 
• Clefts posterior to the incisive foramen 
• Clefting anterior and posterior to the incisive foramen (Allori et al., 2017) 
By 1976 Millard stated that no cleft system “has been universally accepted because of 
language differences, inaccuracies, omissions and (a) lack of simplicity” (Millard, 1976). This 
lack of a universal classification system not only meant that clinicians used broader 
descriptive terms of cleft lip, cleft palate and cleft lip and palate, but also meant that 
auditing and research was problematic due to the heterogeneous nature of the data (Allori 
et al., 2017).  
Currently, most international cleft care teams use a pictographic notation, either the 
Kernahan striped-Y diagram, or written coded notations such as the LAHSHAL classification. 
The LAHSHAL classification was created in 1989 by Otto Kriens and was modified by the 
Royal College of Surgeons, England in 2005 to the LAHSAL classification (Figure 2). LAHSAL 
being a series of letters describing the 6 parts of the mouth that can be affected by clefting, 
namely: L – Right Lip, A – Right Alveolus, H – Hard palate, S – Soft palate, A – Left Alveolus, L 
– Left Lip. 
If the cleft is complete, an upper-case letter is used (e.g. S – complete soft palate cleft). An 
incomplete cleft would be noted with a lower-case letter (e.g. s – incomplete soft palate 
cleft). No cleft is left blank. Therefore, a child with a unilateral cleft lip and palate (UCLP) 
would be classified as LAHS or HSAL codes, depending on whether the lip cleft was on the 
right or the left. This is the system used by the CRANE (Cleft Registry & Audit NEtwork) 
database and is used nationally in all UK cleft centres. The purpose of the CRANE Database, 
formed in 2000, was to collect information on children born with cleft lip and/or palate in 
England, Wales and Northern Ireland.  
 
Figure 2. The LAHSAL classification used for the CRANE database. (image adapted from 
Hodgkinson et al., 2005). 
 
2.3 Care pathways for each type of cleft 
 
The care required for the cleft affected child differs to some extent according to the 
phenotype. This current project is focussed on unilateral CLP, bilateral CLP and CP only, and 
therefore only these care pathways will be described. The pathways may differ based on the 
region of the country and the choices of the local cleft team. However, they are broadly 
similar in terms of surgeries, timing of surgeries and the multidisciplinary teams involved. 
 
2.3.1 Diagnosis and Birth 
 
Early diagnosis is key and is one of the principal focusses of cleft care in the UK. Ultrasound 
is used routinely to detect the position of the placenta, the sex of the foetus and congenital 
abnormalities present in the foetus. Diagnosis by ultrasound sonography is a well-
established method for detection of CLP and was first described in 1981 (Christ and 
Meininger, 1981). All women in the UK who are pregnant have a scan at approximately 20 
weeks’ gestation, which involves having a trans-abdominal ultrasound scan. Should any cleft 
abnormalities be found at this stage, the pregnant mother would be referred to the Cleft Lip 
and Palate Unit for counselling (Shaikh et al., 2001). Ultrasound is a non-invasive scan which 
has been found to cause no harm to the unborn child, whilst allowing the benefits of being 
able to prepare for the unborn child’s needs. However, there are some problems associated 
with ultrasound scans. In particular, detection rates can vary significantly and may be 
affected by the experience of the sonographer. Detection rates for CLP range between 16 
and 93 per cent (Smith et al., 2004) and an isolated CP is rarely diagnosed prenatally (Shaikh 
et al., 2001). Even if diagnosed, it is difficult to know if the cleft lip has alveolar or secondary 
palate involvement from an ultrasound alone (Smith et al., 2004). 
There is evidence suggesting that prenatal diagnosis, with adequate support from the cleft 
team, can help the expectant parents to feel more psychologically prepared for the birth of 
their child, and better prepared and aware of the practical aspects of the child’s care and 
the treatment pathways involved (Rey-Bellet and Hohlfeld, 2004). Previously, parents being 
told they are expecting a child with an orofacial cleft may have been more distressed, with 
rates of termination of pregnancy being affected by this knowledge (Chapman et al., 2003). 
More recently, a prospective cohort study has shown that more than half of parents 
expecting a child with oral clefting described it “as a cosmetic disability” (50.6%), or as “just 
a little different” (29.4%).” A minority (6.4%) considered termination of pregnancy, with 
none of the responders choosing to terminate pregnancy (Maarse et al., 2018).  
When an unborn/born child with CLP or CP is diagnosed, a Cleft Nurse Specialist will contact 
the parents through either a telephone call or a visit to the hospital/family home within 24 
hours. This is a good opportunity for the family to ask questions and understand what 
implications the condition may have for the child and the family. The initial referral process 
also starts at this stage. During the early days of life, feeding may be an issue for the child 
(Martin and Greatrex-White, 2013) and therefore feeding and oral care advice can be 
provided to the mother of the child (Beaumont 2012). Should there be complications, the 
multidisciplinary team can provide support as required, including referral to a dietitian or 
lactation team (Donovan 2012). 
 
2.3.2 MDT (Multi-disciplinary team) 
 
Following the recommendations of the Clinical Standards Advisory Group (CSAG) in 1998, to 
make cleft care a more centralised process (Sandy et al., 1998), 57 centres operating on 
orofacial cleft patients in the UK were reduced to just 11 centres, or managed clinical 
networks by 2011. The reason for this change was to improve outcomes for children 
affected with orofacial clefting. The current model is based on a hub and spoke, with the 11 
centres or clinical networks (hubs) co-ordinating the treatment of patients from the smaller 
local hospitals (spokes). This ensures that surgeons who carry out the required procedures 
do so relatively routinely (at the hub), improving outcomes compared to operators with a 
limited caseload (Fitzsimons et al., 2012). Outpatient appointments in many cases continue 
to be provided at the spoke units, in order to allow the children and their parents to travel 
easily to their appointments, minimising disruption to studies/work, and ensuring continuity 
of care with the same local team. 
The cleft MDT comprises numerous professionals involved in the care of the CLP affected 
child. The team includes surgeons (maxillofacial, ENT, plastic surgery), dentists (paediatric 
dentists and orthodontists), speech and language therapists, a cleft nurse specialist and 
psychological support. Early exposure to the cleft team is advised, and generally occurs in 
the first 2 months of the baby’s life. It is a good opportunity for the family of the baby to 
meet the different specialties and to allow patients to better understand what procedures 
are required and what forms of support are available for the baby and their family. There 
are specific cleft clinics run for audit purposes in order to ensure that the different aspects 
of the required treatment are being carried out in a timely manner, in order to give the best 
possible outcomes. These audit clinics are at five-year intervals, namely at aged 5, 10, 15 
and 20 years.  
2.3.3 Unilateral and Bilateral Cleft Lip and Palate 
 
When a baby is born with a unilateral or bilateral CLP, the Cleft Team are contacted by the 
maternity ward and are referred the baby over the phone. The specialist cleft nurse will visit 
the baby on the ward and will discuss with the parents the nature of the cleft and the likely 
impacts. Feeding is assessed and often a different bottle/ teat is provided in order to aid 
this. Home visits are carried out after the baby has left the hospital in order to ensure that 
there are no concerns with feeding and that the parents are coping well. A referral is also 
made to the cleft clinic. 
The first cleft clinic is within the first one to two months after birth and involves the baby 
being assessed by the cleft surgeons in order to plan the surgical repair of the cleft lip. The 
family are introduced to the different specialties including surgeons, orthodontists, 
paediatric dentists and audiologists. The family are also offered psychological support if 
required.  
The first surgery, lip repair, is carried out at approximately three months of age and involves 
the baby staying in hospital with their parents for two to three days (one or two nights). 
Second stage surgery may be required (further lip repair in two stages in the case of a 
bilateral CLP and/ or scar revision of the initial lip repair) approximately three months later, 
which again would be two to three days (one or two nights) in the hospital along with their 
parents. Between the 9th and 12th months, the baby usually undergoes palate repair, also 
under general anaesthesia and this involves a two day (one night) stay in the hospital for the 
child and parents. Should any speech therapy or psychological treatment be required from 
the age of two years, treatment would commence as necessary. Orthodontic and audiology 
assessments begin at five years of age. Treatment with ENT/ audiology can involve 
grommets in children to improve hearing or customised hearing aid provision, whilst early 
orthodontic treatment will mainly involve simple orthodontic alignment of the teeth to a 
correct anterior crossbite. This can be done using an upper removable appliance when the 
upper permanent central incisors erupt at approximately six to seven years of age. 
In the case of both UCLP and BCLP children, more complex orthodontic treatment is likely to 
be required to create space in preparation for canine eruption and associated alveolar bone 
grafting (ABG) at approximately 10 years of age. Grafting requires a hospital stay for the 
child as it is carried out under general anaesthesia (usually two days, one night in the 
hospital for the parent and child). Additional outpatient appointments are necessary 
immediately prior to and after surgery in order to assess the child prior to surgery and also 
to review the post-operative healing.  
Orthodontic treatment is almost always required during the process of managing orofacial 
clefting. The role of the orthodontist in the multidisciplinary team is for record keeping, 
treatment planning and the provision of orthodontic therapy. This will usually be from soon 
after birth, through childhood to adolescence and beyond to adulthood (Cassi D et al., 
2017).  
Facial surgery may be required for correction of a Class 3 skeletal pattern, when growth has 
just about ceased, at approximately 17-18 years old. This usually involves a course of 
presurgical and post-surgical orthodontic treatment in conjunction with either single or two 
jaw surgery under in patient general anaesthesia (usually a one or two night hospital stay). 
In some instances, an osteotomy may not be indicated, and orthodontic camouflage may be 
the appropriate treatment approach.  
Care pathways have been mapped out for individuals with orofacial clefting (Figures 3 & 4). 
The following flow charts are from the South Wales South West Managed Clinical Network – 
Typical Patient Journey flowcharts (2016). They demonstrate care pathways for patients 

























































































































































































































2.3.4 Cleft Palate Only 
 
An isolated cleft palate has a slightly less complex treatment pathway (Figure 5). As with 
cleft lip and palate, when the baby is born, a member of the Cleft Team initially meets the 
family in order to facilitate feeding and the referral process.  
This is followed by an assessment in the cleft clinic, in which the baby is referred to the 
paediatric dentist and the family are offered psychological support if it is required. At 6 
months of age, the baby has surgery to repair the palate, with a review being carried out 6 
months following the surgery. This is different to treatment of cleft lip and palate, in which 
the lip repair is initially carried out at 6 months, followed by palate repair at between the 9th 
and 12th months.  
The baby is periodically assessed on several cleft clinics, with psychological and speech 
therapy assessments beginning at two years of age as necessary. Orthodontic and audiology 
assessments begin at 5 years of age. Treatment, if required, would be carried out when 
planned to be most appropriate. This pathway contains fewer surgical interventions and 
therefore fewer hospital in-patient stays. Patients are seen by the paediatric dentist every 6 
months to a year (unless otherwise seen in community) and cleft clinics at least once a year, 












































































































The surgeries that CLP and CP affected individuals require are predominantly in the first 
year of life (including lip and palate repair) for primary surgery, followed by an alveolar bone 
graft at around 10 years if necessary. Primary repair may be carried out in two stages 
depending on various factors such as the size of the cleft, the health of the baby, and the 
success of the initial operation. This primary surgery may be carried out at different times 
around the world due to ongoing debates as to the best timing with respect to appearance 
and speech outcomes. Some care providers feel that surgery to repair the palate prior to 
nine months of age is most beneficial to speech outcomes. Others perform palate repair at 
12 to 18 months of age to minimise any detrimental effects of surgery on growth (Sitzman 
et al., 2017).  In the UK, within the first year following birth, the initial surgeries are 
completed. This involves early repair of the lip, within the first three to four months, 
followed by the surgery to repair the palate ideally between six to nine months of age.  
Historically, it has been said that “Millard’s Rule of 10” should be followed with regards to 
carrying out surgery, i.e. infant’s body weight of 10 pounds, haemoglobin count of 10g/dl, 
and older than 10 weeks. Much work has been done since showing that this should not be a 
rigid guideline, and that surgeries can be carried out earlier if required with good 
justification, especially with modern advances in paediatric anaesthesiology, which allow 
safer anaesthesia of infants (Ibadurahman and Sudjatmiko 2012). 
2.4 Health Economics  
 
Healthcare economics involves making decisions about allocation of resources where 
resources are finite, but demand is infinite (Morris 2012). These resources can be defined as 
time, money, materials and attention of the staff. All these resources could be used in other 
services or different industries. This results in a mismatch of what is available, compared 
with what is required, as the resources are limited. It is on this basic principle that we can 
better understand how the healthcare system works.  
In the UK, healthcare is largely provided by the publicly funded National Health Service 
(NHS). The NHS is given a fixed budget from the UK government (money allocated from 
taxation), which is then assigned for a number of different healthcare applications. This 
includes staffing, materials, hospitals and clinics, research work, medicines and training of 
healthcare professionals. The NHS has commissioning and procurement teams and it also 
outsources contracts to non-NHS subcontractors for certain services. Currently the 
healthcare system is facing not only continually increasing costs for materials and services, 
but also an increased demand for its services. This is as a result of a growing population that 
is surviving far longer as a result of modern advances in medicine, with improved access to 
resources, and alongside the development of new drugs and treatments, which tend to be 
more costly. 
Healthcare systems typically aim to maximise the efficient use of available resources, whilst 
providing the greatest benefits to the users of the healthcare services (the population). 
Health benefits can be measured in a number of ways, for example years of life saved, or 
quality of life changes. Money and time are spent on the healthcare system and it is 
important to analyse if this is providing good value for money.  
The NHS, in the course of trying to provide a number of services, attempts to deliver each of 
these services in a cost-efficient manner, whilst taking into account quality (Buck, 2000). The 
latter can be measured in a number of ways. For example, markers of quality might include: 
the number of surgeries that need re-visiting, length of hospital stays, infection rates, or 
quality of life improvements to name just a few. 
As the NHS is a public-sector service, there is no direct monetary profit made from the 
achievement of better health in the UK. Although spending might decrease the need for 
further treatment and improve overall health, it can be difficult to identify as a direct 
financial benefit. As a result, healthcare systems have to use alternative measures, other 
than profit, to assess whether a service is being carried out efficiently, effectively and at a 
gain to the population, relative to spending on other potential services. Economic 
evaluation draws on the principle that if one service is provided, another service is unable to 
be provided due to limited resources and is defined as the “comparative analysis of 
alternative courses of action in terms of their costs and consequences” (Drummond et al. 
2015). The opportunity costs in a healthcare system are defined as what “could have been 
achieved had the money been spent on the next best alternative intervention or healthcare 
programme” (Palmer and Raftery 1999). 
Therefore, the distribution of available funds must be evaluated carefully in order to ensure 
resources are allocated appropriately and efficiently.  If budget allocation and cost analyses 
are not carried out efficiently, there can be significant consequences. These can include 
waste, both in terms of time and resource, but also the opportunity cost of these resources: 
resources which may have otherwise been used to benefit other users of healthcare in the 
population. 
Economic evaluation is a tool that helps optimise the distribution of resources spent in 
getting the maximum healthcare benefits in a financially constrained system. It is also 
important to appreciate that healthcare economics are based on a population and not on an 
individual basis. To maximise the health of the population, individual needs are not 
necessarily always met, as it the maximum health benefits to the population at large that 
are considered. Economic analysis is carried out by comparing resources used, against 
measured health outcomes, and compares alternative treatment methods and modalities, 
or different structures of providing care in terms of outcomes or costs. The main methods 
used to carry out economic analysis are (Kumar et al., 2006): 
• Cost minimisation analysis 
• Cost effectiveness analysis 
• Cost utility analysis 
• Cost benefit analysis 
2.4.1 Cost minimisation analysis 
 
Cost minimisation is generally used when costing is the main variable, with similar or 
unchanged outcomes (Robinson, 1993).  This process involves assessing the costs of each of 
the individual interventions, allowing the most inexpensive intervention to be identified 
where there are similar outcomes (Kumar et al., 2006). Currently cost minimisation is 
discouraged, as it can be significantly biased where there is uncertainty of costs and large 
variations in the treatment costs. As a result, it can lead to an over or underestimation of 
costs. Instead, cost effectiveness analysis has been found to be more appropriate in 
avoiding biased estimations of uncertain costs (Dakin and Wordsworth, 2013). 
2.4.2 Cost-effectiveness analysis 
 
Cost-effectiveness analysis is useful in comparing interventions which may differ in terms of 
outcome, but have a standard unit of measure (Robinson, 1993). This process involves 
comparing the costs of interventions directly using common units, such as lives saved, days 
that pain killers were not required, or other common variables. This process relies heavily 
on assumptions that the patients may have all had similar experiences with the outcomes 
used, and only the one-dimension unit of comparison is the variable. As a result, it may be 
seen as a limited method. This is because it does not provide a true representation of the 
subjective experiences that individuals may have, and it does not allow comparison across 
disease areas, which is necessary for resource allocation (Kumar et al., 2006). 
2.4.3 Cost-utility analysis 
 
Cost-utility analysis is a subset of cost-effectiveness analysis and is a method of comparison 
of interventions which do not have a standard unit of measure of clinical outcomes 
(Robinson, 1993). Utility values are numbers representing “parameters which influence a 
person’s well–being (Kumar et al., 2006).” Utility values are typically measured using the EQ-
5D health-related quality of life tool (Clarke et al., 2002). This tool evaluates quality of life 
and has population values assigned to each health state. The utilities are anchored at 0 and 
1, where 1 is perfect health and 0 is death (Kumar et al., 2006). There are also negative 
values that are considered to be worse than death. This utility value can be used in a simple 
calculation to calculate the ‘quality adjusted life years’ (QALYs), which acts as a standardised 
unit of measure to be able to directly compare interventions (Drummond et al., 2015). 
QALYs combine both length of life and quality of life into a single number. Using QALYs to 
measure outcomes has been criticised due to certain treatments for non-life-threatening 
conditions being ranked higher in QALY than life threatening conditions.  
The National Institute for Health and Care Excellence (NICE) has a role in helping the 
healthcare system deliver care to the best standards possible within the available resources. 
NICE uses QALYs to assess if interventions are good value for money in terms of how much 
of an improvement a cost will make. However, it is not the sole way in which decisions are 
made, and should there be other grounds for an intervention to be used it may still be 
justified. QALYs are also a good way of measuring the benefits of treatments, whilst 
comparing different diseases and treatment modalities in a consistent way. Typically, NICE 
has mentioned an intervention which costs below £20000 per QALY to be cost-effective; if it 
was up to £30000, it would be cost effective if it could be justified (Ogden, 2017).    
2.4.4 Cost-benefit analysis 
 
The cost-benefit analysis is “considered to be the most flexible method of economic 
evaluation” (Robinson, 1993). This process is rarely used, particularly in the UK as the 
healthcare system is paid for by the state. Patients are not specifically “shopping” for 
healthcare and are thus unaware of the costs involved at times. As a result, “willingness-to-
pay” studies, which can help cost outcomes, can be both difficult to conduct and 
inconsistent.  
The process is carried out by calculating and placing values in monetary terms on the inputs 
and outputs of the system. In a healthcare system, the treatment costs are the inputs and 
the consequences are the outputs. This allows direct financial comparison of costs which are 
in the healthcare system, and costs which are outside of this system, such as environmental 
and education costs. 
2.4.5 Economic evaluation of CLP 
 
Within the current literature, there are a limited number of papers investigating the costs of 
cleft care. The first of these studies carried out a survey across the 16 UK cleft centres that 
were functioning at that time, on the management of otitis media with effusion in cleft 
palate affected children. It reported that 90% of children with CP have otitis media with 
effusion histories. The treatment cost per child (from cost year 2010-2011) varied between 
£593 (with no active treatment being carried out) and £2663 (insertion of ventilation tubes 
and hearing aid provision), depending on the choice of treatment (Bruce et al., 2015).  
Another study by Mohiuddin et al. (2015), looked further into these costs by carrying out a 
cost-effectiveness analysis of treatment of otitis media using grommets in children with CP. 
This study adopted a decision tree model in order to assess surgical grommet insertion, with 
alternative options not involving surgery (e.g. hearing aids, or no active treatment). The 
study concluded that grommets were more cost-effective compared with hearing aids or 
antibiotic treatment methods. However, the study did not provide a measured cost of the 
treatment of otitis media in children with CP. 
Another study observing CLP demographics, prevalence and complications in California over 
a 15-year period, with a yearly average case-load of 697 and a total number of correction 
surgeries over the 15-year period of 10,450, showed total median charges of $35,643 by the 
end of the study period in 2011 (Mahboubi et al., 2015). With revision surgeries being 
relatively common, this is a large expense. Although the results of this study are not likely to 
be directly comparable to the UK with its publicly funded NHS, it does illustrate that the 
provision of care for children with CLP may be associated with considerable costs.   
By contrast, a study in Uganda of 343 cleft lip and cleft palate repairs, as a part of the 
training scheme for local surgeons by surgeons from overseas, the cost was just £27 per 
cleft repair. However, this cost did not take into account the expatriate staff salaries as the 
care was provided on a voluntary basis (Hodge and Hodges 2000). Therefore, the cost of 
care can vary greatly for different countries of the world and is likely due to many factors, 
including but not limited to differences in staff salaries, material costs, and the facilities 
where the care is provided in the different parts of the world.  
Other studies in the USA have also attempted to analyse the costs of CLP associated 
surgeries. One study looked at 2,380 patients attending for cleft lip repair in 2010 and 
reported mean charges per patient for hospitalisation of $24,779 (Allareddy et al., 2014). 
The same authors had also carried out previous work into the factors associated with 
hospitalisation costs of cleft palate repair or revision, and reported mean hospital stays 
costs of $19,227. In this work, the authors describe a lifetime expenditure for orofacial clefts 
in the USA as being valued at $100,000, and describe not only might this be outdated, but 
that it can vary significantly with geographic location (Allareddy et al, 2012). 
Another study attempted to carry out an analysis to assess the economic impact of cleft 
care in resource poor settings. A cost analysis, estimating how much impact was made by 
the surgeries carried out, assessed 1,142 reconstructive surgery cases over a 15-year period 
in Ecuador. Information was gathered from the logbooks supplied by “Hands Across the 
World,” a charity for vulnerable children. Of these surgeries, cleft disorders constituted 277 
cases, and 102 cases were individuals with primary cleft lip and/or palate. The study found 
that of the 102 cases of primary cleft repair “between 396 – 1042 total disability-adjusted-
life years were averted through surgery. This translates to an economic benefit between $4.7 
million (human capital approach) and $27.5 million (value of a statistical life approach)” 
(Hughes et al.,2012). However, this economic benefit approach does not provide a cost for 
the provision of care for individuals with CLP and is instead based on calculations of costs 
associated with disability-adjusted life years. 
There is clearly limited evidence on the true costs of caring for children and adults affected 
by orofacial clefting and the costs will vary greatly across the world. To date no studies have 
effectively highlighted the costs of cleft care in the UK, nor indeed the world. The NHS 
provides care for patients with orofacial clefting, and it is important to know what this 
tertiary level of care provision costs the healthcare system, in order to make provisions for 
this service during budget allocation. It would be beneficial to assess the costs in order to 













3. Aims and Objectives 
 
3.1 Aims of this study 
 
The aim of this study was to undertake a micro-costing approach to determine the 
secondary care costs to the National Health Service (NHS) associated with the cleft care 
pathway of patients being treated from birth until 10 years of age for UCLP, BCLP and CPO. 
This was compared to NHS reference and tariff costs. 
3.2 Objectives of this study 
 
The objectives of this study were: 
1. To identify the patient records at the Bristol Cleft Unit using the local database of 
children with cleft treated post CSAG from birth to 10 years of age. 
2. Within this retrospective cohort of 30, obtain the records of 10 individuals with 
complete and incomplete unilateral cleft lip and palate (UCLP), 10 with complete and 
incomplete bilateral cleft lip and palate (BCLP) and 10 with cleft palate only (CPO).  
3. To interrogate these records and use the data to identify the itemised costs of cleft care 
to determine the total cost of secondary cleft care to the NHS from birth to 10 years of 
age for each of the three cleft phenotypes 




4. Materials and methods 
 
Approval to carry out a cleft care service evaluation, with a view to reviewing the funding of 
the cleft service in the South West, was granted by the University Hospitals Bristol and 
Weston NHS Foundation Trust (UHBW) Caldicott Guardian on 19th April 2018. 
The service evaluation was facilitated by the South West Cleft Team, and access to records 
was facilitated by the Clinical Director of the Cleft Team, Mr Scott Deacon. Previously 
mapped care pathways were used to assess the ideal pathway for an individual born with 
orofacial clefting. The pathways mapped by the South West Cleft Team for children born 
with UCLP, BCLP, and CPO from the ages of 0 to 10 years, with no associated syndromes, 
were used to carry out this cleft care service evaluation. 
4.1 Materials required 
 
- Laptop – Apple MacBook Air (password protected) 
- Microsoft Excel, with a customised spreadsheet – Microsoft Corporation, One 
Microsoft Way, Redmond, Washington, United States, WA 98052-6399 
- Secure storage device to keep data secure and compliant with General Data 
Protection Regulation (GDPR) – iStorage DatAshur PRO 256-bit USB Flash Drive 
4.2 Inclusion 
- Patients registered on the CRANE database with either UCLP, BCLP or CPO 
- Patients who were over the age of 10 years, in order to be able to collect 10 years of 
retrospective data (birth to 10 years of age) 




- Patients who presented with a syndrome associated with the orofacial clefting 
4.4 Care Pathway 
 
Patients are seen within the cleft department at UHBW from birth. The cleft pathway 
(Figure 6) displays the journey of a patient who presents to the cleft team based on which 
one of the three phenotypes they present with. 
 
Figure 6. Simplified version of typical cleft care pathway of the three cleft phenotypes 
between ages of birth and 10 years old, modified from South Wales South West Managed 
Clinical Network – Typical Patient Journey flowcharts (2016)  
 
 
4.5 Identification of patients  
 
Although 10 individuals from each of the three phenotypes (30 in total) were to be studied 
only 23 could be identified using the agreed inclusion and exclusion criteria of the study 
applied when applied to the local source database (5 BCLP; 8 CPO; 10 UCLP). The clinical 
notes were requested from the central hospital records at UHBW with the help of the cleft 
department and obtained following study approval. The notes were initially securely stored 
in a locked room and were then transferred to the South West Cleft Team offices at the 
University of Bristol Dental Hospital for data collection. 
 
4.6 Data collection 
 
The hospital records for each of the patients involved in the study were interrogated in 
order to determine the number of hospital appointments they had for each of the different 
outpatient / inpatient specialties associated with cleft care. The following data were then 
collected and entered onto a Microsoft Excel spreadsheet and stored on an encrypted USB 
drive stored in a locked office: 
a) Number of hospital appointments (and any relevant information): 
- Cleft clinics (Single specialty) 
- Joint cleft clinics  
- Cleft nurse review (including inpatient, outpatient or telephone review) 
- Speech and language therapy (SALT) (including school visits, home visits and 
telephone reviews) 
- Psychology clinics 
- Paediatric dentistry clinics 
- Orthodontic clinic appointments 
b) Surgeries involving cleft repair (including any medicines prescribed)  
c) Duration of theatre time and recovery 
d) Duration of inpatient visits due to cleft surgery 
It became evident from letters and correspondence that much of appointment data was 
missing from the hospital notes, namely the SALT and Ear Nose and Throat (ENT) data. 
Following a discussion with the SALT team, it transpired they filed their own notes in their 
own department(s). Similarly, the ENT data was stored in a different unit within UHBW, 
namely St Michael’s Hospital, rather than in the main UHBW records department. The 
missing SALT and ENT records were therefore requested and both the paper and digital 
notes were assessed.  
Treatment for most of the children was carried out in the Bristol Children’s Hospital. 
However, in certain cases, some of the treatment was carried out in the spoke hospital and 
in two isolated cases, treatment was carried out at other hospitals outside of the South 
West region due to family relocation. Due to the relatively low number of clinical notes 
available, these isolated cases had data collected where available. The durations of 
surgeries or the documented inpatient stays had the costs of the particular hospital applied, 
assuming that the duration of hospital inpatient stays or the surgery times would otherwise 
have been similar in other departments.  
Some of the community-based treatment could not be assessed. Dental treatment and 
audiology were examples of such treatments that were sometimes carried out in the 
community setting, and sometimes in the hospital.  
When there were any queries relating to the general data or logistics, advice was sought 
from the Clinical Director of the Cleft Service. In the event of any issues with audiology, SALT 
or ENT data, the SALT team were happy to help and provide direction as to how the queries 
could be addressed. 
Where information was missing; advice was taken from the Clinical Director of the cleft 
service and Dr Thorn (Health Economist), one of the academic supervisors for the study. It 
was decided that missing appointments would not be estimated. Surgical missing 
information was estimated using collected averages of similar data. Where data was missing 
from the notes this was recorded as such on the spreadsheet. 
Where possible, for each activity the following was recorded in the spreadsheet: 
• The date  
• The time required  
• Any consumables used 
• Whether it was inpatient or outpatient 
• Pharmaceuticals used   
• Letters written 
• Staff present and grade 
• Duration of the activity 
Using this information, the costs for each individual activity were then calculated.  
 
 
4.7 Staff costs 
 
Staff costs are published by the NHS and can be accessed in the document “Agenda for 
Change” (NHS Employers, 2019). Using this document, a table was constructed in Excel to 
calculate the pay scales of the members of staff involved in the care of orofacial clefting.  
Staff were all on different points of the salary scales in line with other responsibilities or 
levels of experience that they may have, and it was deemed to be inappropriate to ask them 
directly where they were on the pay scales. As a result, salaries from NHS job 
advertisements and discussions with both line managers and the Clinical Director of the 
Cleft Service were used to estimate the best cost salaries for staff and appropriately band 
their salaries within the NHS staff banding.  
The yearly salaries of members of staff involved in the care pathway was divided by the 
number of working days in a year, which is 221 (as a result of annual leave, study leave and 
weekends), followed by dividing this by the working hours in a day. Salaries were placed 
into bands, or Consultant pay scales, and were categorised to the levels of experience.  
The national insurance and pension contributions were also added to the salaries, in order 
to correctly calculate the cost to the employer for the staffing. This was found to be 14.38% 
in line with the NHS Business Services Authority. The salary per minute was therefore 
multiplied by 1.14, and a cost per minute for the staff was calculated from the annual 
salaries. The per minute salary was used in order to calculate costs of each of the clinical 
episodes.  
The boundaries of the pay scales were used to calculate the upper and lower bounds of the 
staff costs and a midpoint of the salaries was also calculated in order to give an estimated 
range of what the cost might be. 
Because this was a retrospective study, with clinical notes which did not have the durations 
of outpatient visits, or clinic durations, average clinical times and not exact amounts of time 
spent per patient were used. Outpatient appointments were discussed with the booking 
staff to assess the length of each outpatient appointment. Exact appointment times were 
not available in the notes, only the date of the activity and the associated clinical coding. 
Expert opinion was sought from the Clinical Directorate of the Cleft Service in order to 
estimate the length of clinic appointment times. The investigator also attended a joint clinic 
and appointment durations were assessed. This corroborated with the estimated times and 
so the booking times were assumed to be correct estimates of how long was spent with 
each patient. Appropriate departments were also consulted to accurately estimate if 
booked times were a true reflection of time spent on each patient. This was a pragmatic and 
robust way of calculating clinical appointment costs retrospectively.  
Inpatient durations were calculated from entries in the clinical notes and were also used to 
estimate the nursing costs. Surgical theatre times were determined in order to calculate 
staffing costs per minute of surgical time. Although the surgery inpatient dates were 
present, sometimes no operating theatre times were recorded. In this case, an average of 





Consumable costs were calculated for both inpatient and outpatient appointments for each 
patient. Consumables included costs associated with sterilisation of multiple-use items such 
as surgical instrument kits and costs of single-use items such as personal protective 
equipment (PPE). 
4.9 Outpatient appointments 
 
Sterilisation costs for outpatient appointments were found by meeting with the 
management of the Central Sterile Services Department (CSSD). As outpatient appointments 
involved using a sterilisable tray of instruments, the sterilisation cost for a tray of 
instruments was used as an estimated given cost associated with specific clinical 
appointments. The appointments chosen to have this assigned cost (cleft clinic, joint cleft 
clinic, single specialty clinic (including ENT and Orthodontics), speech investigation, cleft 
nurse review and paediatric dentistry) were elucidated by discussing with the clinical teams 
attending these clinical appointments. The management of the CSSD estimated that the 
costs for sterilised outpatient trays were approximately £20. 
The other clinics such as the cleft audit clinics rarely used sterilisable clinical trays and this 
was therefore not an assumed cost for these other appointments. Single-use items for 
outpatient appointments such as disposable gloves for the clinician, or a disposable plastic 
mirror were also not added due to their low cost i.e. less than 20 pence. Indeed, they may 
be included in the overheads associated with some clinical areas, and not including them as 
a separate cost reduces the risk of double counting. 
 
4.10 Inpatient and surgical appointments 
 
All of the procedures carried out required different levels and types of equipment and 
consumables. To establish the cost for consumables used in surgeries associated with 
orofacial clefting, I visited the paediatric surgical theatres at UHBW where the surgeries 
were carried out. 
Lists of equipment required for each type of procedure were provided by the theatre staff 
and included both multiple-use instruments, which require sterilisation, and single-use 
items. A list of sterilisation costs was obtained from the Head of the CSSD at UHBW for each 
piece of equipment. Costs for single-use items were found by the Head of the CSSD using 
previous order invoices. A theatre session involving orofacial cleft repair surgery was 
attended by myself in order to validate these equipment lists, from which an appropriate 
assumption of the costs could be made. These lists for each surgical procedure were then 
used to appropriately cost each of the surgical procedures. Time was added for buffer time 
around the surgery during which surgical checklists are performed and consent is 
checked/patient is sent for. When the theatre is cleaned, notes are written at the same 
time. This buffer time was deemed to be 40 minutes (20 minutes either side of the surgical 
time noted) and was discussed with numerous operating surgeons in order to ensure it was 
a fair representation. 
4.10.1 Pharmaceuticals 
 
After interrogating the notes, it was found that at outpatient appointments, not only were 
medications rarely prescribed, but when they were prescribed, they were usually analgesics, 
which are relatively inexpensive. As a result, only medications associated with inpatient 
hospital stays (due to surgical procedures) were considered. 
Inpatient medications can be split into anaesthetic medication costs, and medications taken 
home by the patient following the hospital stay, i.e. ‘to take away’ medications (TTA). 
4.10.2 Anaesthetic medications  
 
Anaesthetic medications were noted on drug charts present in the clinical notes and were 
similar for the various surgical procedures carried out. Using the medications found in the 
notes, and following discussions with anaesthetists both during the surgical procedure 
observed, and an anaesthetic consultant from UHBW, a list of average medications was 
compiled (fentanyl (500mg), propofol (200mg), atracurium (50mg), ondansetron (4mg), 
dexamethasone (6.6mg), co-amoxiclav (1.2g), IV paracetamol (1000mg), Hartmann’s 
solution (1 litre), sevoflurane (per hour)), which was applied to all of the surgical 
procedures, per patient, in order to keep costs standardised.  The list of medications was 
costed using the most up to date British National Formulary (BNF) at the time of writing, 
using costs per ampule, except for sevoflurane, which is costed per hour (then calculated 
per minute). 
4.10.3 TTA medication 
 
The discharge summaries and clinical notes were used to determine the medications which 
were prescribed on discharge along with discussions with the cleft team. The medications 
were analgesics, antibiotics and a mouthwash (paracetamol (32 tablets), ibuprofen (24 
tablets), chlorhexidine (300 ml bottle), co-amoxiclav 500/125mg (21 tablets)). Each 
medication was costed using the BNF in the same way as anaesthetic medications. 
4.11 Overheads 
 
These were determined with the help of the Finance Department at UHBW and included: 
property maintenance, disposal of waste, utility charges, portering services, provision of 
uniforms, laundry costs, catering, rents and charges and capital charges.  
Highly detailed cost lists were provided by the finance department which included costs of 
staffing. Some staffing costs were reviewed and removed in order to prevent double 
counting. These included consultant costs, as consultant time was specifically accounted for 
when costing appointments or surgery.  
4.11.1 Outpatient appointment overheads 
 
These were determined by multiplying the specific clinic time in minutes by the 
£1.21/minute outpatient overhead cost provided by the Finance Department. 
4.11.2 Inpatient appointment overheads 
 
These were split into ward stay costs and theatre costs. Following discussions with the 
Clinical Theatre Manager at UHBW, it was found that following all cleft surgery, patients are 
taken to the same ward if paediatric (Ward E602). The Finance Department provided an 
overhead cost of £286.34 as a per night cost for this particular ward. This cost was 
multiplied by the number of inpatient nights recorded from the notes. 
Theatre overheads costs provided by the Finance Department were found to be £2.21 per 
minute of theatre time. This cost was multiplied by the time spent for the specific surgical 
procedure and the time spent in recovery for each patient. 
4.12 Total costs 
 
Total costs were found by adding outpatient and inpatient total costs. Statistical analysis 
was carried out to calculate mean costs and standard deviations from mean costs. Total 




















The data were analysed using Stata version 16 (Stata Corp, College Station, USA) statistics 
package and are presented as summary statistics of the costs using means, medians, 
maxima and minima as well as percentages. 
The results are presented under two main categories:  
1.  The overall cost of care for each of the three phenotypes (BCLP, CPO, UCLP). 
2. Costs of inpatient and surgical care compared with outpatient appointments. Clinic 
appointments where patients ‘Did Not Attend (DNA)’ have been included in total 
costs unless specified otherwise.  
 
The results are presented from the median point of staff salaries unless otherwise specified. 
Costs have been calculated using the minimum, median and maximum salary points for 
each staff type involved in the Cleft care pathway. 
 
Prenatal costs are included in the cleft budget and have not been included in this study. This 
would require further data collection and appropriate ethics approval for the parents of the 
individuals with the clefting. It was therefore deemed to have birth as the start point of 
where costs would be calculated from. 
 
 
5.1 Overall cost of care for each of the three phenotypes (BCLP, CPO, UCLP) 
 
There was a large spread in the BCLP (5 cases) total mean treatment cost, with the mean 
cost £17,004.09 (SD £7,361.83).  
A similar wide range in the total cost of provision of care was seen in the BCLP cohort and 
was also seen in the cases of both the CPO (8 cases) and UCLP (10 cases) cohorts, with mean 
costs £6,137.49 (SD £2,319.87) and £11,619.74 (SD £2,547.81) respectively. However, as 
might be expected, the standard deviations for CPO and UCLP are significantly less than for 
BCLP. Proportionately, UCLP displays the lowest standard deviation from the mean cost. The 
larger cohort size for the UCLP group mitigates outlier results and gives a standard deviation 
closer to the mean.  
Table 2 provides the mean overall cost of care for children born with each of the three 
phenotypes from birth until 10 years of age (up to and not including the 10-year audit 
clinic).  
Phenotype Mean overall cost of care Range of costs 
BCLP £17,004.09  £7,666.93 to £26,524.37 
CPO £6,137.49 £3,263.42 to £9,393.06 
UCLP £11,619.74 £7,665.61 to £16,038.72 
Table 2. Mean costs and range of costs for total cost of care of the three phenotypes per 
individual from birth to 10 years old (using median salary costs). 
 
 
5.2 Surgical and inpatient costs compared with outpatient costs 
 
The mean costs for the two categories were identified for each of the three phenotypes. 
Figure 7 clearly illustrates that the surgical costs formed a greater proportion of the total 
costs across all three groups.  The surgical and inpatient costs for BCLP made up 69.4% of 
the total costs compared with UCLP, which were higher at 74.4%, even though the actual 
cost was greater for BCLP.  This is explained by the higher total outpatient costs for BCLP 
compared with UCLP (Figure 7). CPO surgical and inpatient costs were significantly reduced 
at 54.9%.  
Total outpatient costs were similar for both CPO (£2,863.43) and UCLP (£2,973.78) 
respectively showing that the surgical costs for UCLP are generally higher (as we would 
expect as UCLP requires more surgical intervention (also illustrated in the mapped care 




Figure 7. Mean costs (£) for outpatient and inpatient/surgical costs for each of the 3 
phenotypes between birth and 10 years of age. 
 
The overall mean costs for the provision of care from birth to 10 years of age for all three 
groups is shown in Figure 8. The variation between each group is specifically related to the 
salary points (minimum, median and maximum) of staff involved in the care of each of the 
phenotypes.   
 
In the BCLP cohort, the lowest salary point for staff was a mean total of £16,237.51, whilst a 
maximum salary of staff equated to a £17,805.71 (£1,568.20 difference). For the CPO group 
these costs had a range from £5,894.54 to £6,382.91 (£488.37) and in UCLP these costs 
were £11,093.12 to £12,171.57 (£1,078.44). This reflects the reduced staff input in the 
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Figure 8.  Overall mean cost of provision of care (£) from birth to 10 years of age (and not 
including the 10 years of age audit clinic) for minimum, median and maximum salary points. 
 
Figure 9 illustrates the surgical cost for each patient with respect to the surgical 
interventions they underwent as part of their treatment, and for each of the three cleft 
phenotypes. There were some very obvious differences in the costs that can be attributed 
to phenotype. For example, alveolar bone graft (ABG) is carried out in BCLP and UCLP 
cohorts, but not CPO, although the costs for this are surprisingly similar for both BCLP and 
UCLP phenotypes. Bilateral lip repairs in BCLP cost more than unilateral lip repairs found in 
BCLP or UCLP. This would be expected due to complexity differences in the surgical 
procedures. In three of the five BCLP cases, bilateral lip repairs were not carried out. In 
these instances, two (separately timed) unilateral lip repairs were carried out in order to 
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Palate re-repairs were found in all three phenotypes at similar costs. Grommets were least 
common in the BCLP group. Palate repair cancellations were found only in the CPO group 
and were charged at the bed cost for the night only. Palate repair was the most common 
surgery, as all patients would require this procedure to be carried out regardless of which 
phenotype they were, whilst lip repair would not be carried out in CPO. 
 
 
Figure 9. Surgery and inpatient costs plot (£) for each patient and for each surgery type 
within the three cohorts. BCLP costs are the highest total mean costs, with individuals 
needing a greater amount of surgical input. CPO costs are the lowest total mean costs as 
these individuals require the least total surgical input. 
The average cost for each surgical intervention along with the attributed percent costs are 
shown in Table 3. It can be seen that staffing costs make up largest percentage of each of 
the surgical costs, ranging from 35 to 57% of the total cost of the procedures (£696.59 to 
£1439.86). Consumable costs were highest in the case of the ABG due to the materials 
required for augmenting a bone graft. All other surgical procedures had similar consumable 
costs. Anaesthetic consumables accounted for 1-3% of the costs of overall surgical 
procedures and were a fixed cost of £42.60. The bed cost of £286.34 (which was a fixed cost 
for 1 night) formed between 10 and 20% of the overall surgical cost. Overhead costs were 
calculated from the time taken to carry out each procedure and formed approximately 13% 
to 18% of the total mean cost of each of the procedures, ranging between £250.39 and 
£459.68. 
Table 3. Average costs and percentage of total for each surgical procedure split into consumables, anaesthetic consumables, pharmaceutical 
drugs taken home by the patient after the procedure, cost of bed per night (assuming an average of 1-night stay), costs of average overheads 
and the staff costs. 
Surgery Number Mean Cost  SD 





TTA Bed per night Average overheads Staff 
ABG 16 £2,824.30 £215.79 £1,099.59 38.93% £42.60 1.51% 7.32 0.26% £286.34 10.14% £391.17 13.85% £997.32 35.31% 
Bilateral lip repair 2 £2,301.80 £532.79 £309.79 13.46% £42.60 1.85% 7.32 0.32% £286.34 12.44% £459.68 19.97% £1,196.11 51.96% 
Grommet 8 £1,192.42 n/a n/a n/a n/a n/a n/a   n/a n/a n/a n/a n/a n/a 
Lip and palate repair 1 £2,527.87 n/a £309.79 12.25% £42.60 1.68% 7.32 0.29% £286.34 11.33% £442.00 17.49% £1,439.86 56.96% 
Lip re repair 1 £1,837.05 n/a £309.79 16.86% £42.60 2.32% 7.32 0.40% £286.34 15.59% £331.50 18.05% £859.54 46.79% 
Palate re repair 12 £1,565.17 £184.18 £281.97 18.02% £42.60 2.72% 7.32 0.47% £286.34 18.29% £250.39 16.00% £696.59 44.51% 
Palate repair 22 £1,953.37 £329.11 £281.97 14.44% £42.60 2.18% 7.32 0.37% £286.34 14.66% £304.76 15.60% £1,030.42 52.75% 
Palate repair 
cancelled 2 £286.34 n/a n/a n/a n/a n/a n/a   n/a n/a n/a n/a n/a n/a 
Pharyngoplasty 1 £1,713.88 n/a £209.14 12.20% £42.60 2.48% 7.32 0.43% £286.34 16.71% £309.40 18.05% £859.12 50.13% 
Unilateral lip repair 15 £2,204.85 £442.32 £309.79 14.05% £42.60 1.93% 7.32 0.33% £286.34 12.99% £367.74 16.68% £1,191.10 54.02% 
5.3 Costs per outpatient appointment 
 
Clinic cost breakdowns for each outpatient appointment variation are shown in a series of 
tables (Table 6 to 21) and show which members of staff were present in those clinics. The 
percentage of the total cost of each clinic is given for costs associated with:  
- Staffing 
- Overheads  
- Consumables  
Outpatient appointment durations were found by discussions with the booking teams and 











Clinical Appointment Time in minutes 
Cleft clinic 15 
Joint cleft clinic 15 
Single specialty clinic (including 
orthodontics and ENT) 15 
Audit clinic 15 
Speech investigation 15 
Cleft nurse review 15 
Cleft nurse phone call 10 
Cleft nurse home visit 60 
Paediatric dentistry 20 
Audiology 15 
SALT face to face 30 
SALT telephone review 15 
SALT school group session 60 
SALT school or home 60 
SALT and psychology 30 
Photography 15 
Psychology 30 




The staff present at each clinic are detailed in the following table (Table 5).  
Clinical Appointment Staff 
Cleft clinic 
1 consultant surgeon, 1 consultant orthodontist, 1 specialist 
nurse 
Joint cleft clinic 
1 consultant surgeon, 1 consultant orthodontist, 1 
psychologist, 2 SALT 
Single specialty clinic 1 consultant, 1 specialist nurse 
Audit clinic 
1 consultant surgeon, 1 consultant orthodontist, 1 
consultant paediatric dentist, 1 specialist nurse, 1 
psychologist, 2 SALT 
Speech investigation 
1 consultant surgeon, 1 consultant orthodontist, 2 SALT, 1 
radiographer 
Cleft nurse review 1 specialist nurse 
Cleft nurse phone call 1 specialist nurse 
Cleft nurse home visit 1 specialist nurse 
Paediatric dentistry 1 consultant paediatric dentist, 1 specialist nurse 
Audiology 1 audiologist, 1 nurse 
SALT face to face 1 SALT 
SALT telephone review 1 SALT 
SALT school group 
session 1 SALT 
SALT school or home 1 SALT 
SALT and psychology 1 SALT 
Photography 1 medical illustrator 
Psychology 1 psychologist 
Table 5. Clinicians present in each clinical appointment variety 
 
Staffing costs associated with the ‘cleft clinic’ contributed to the majority of the costs 
associated with this outpatient appointment, with the percentage being 50.1% of the total 

































Minutes 15 15 15 
Staff cost – minimum salary point (£) 14.1 14.1 4.35 
Staff cost – median salary point (£) 16.65 16.65 4.95 
Staff cost – maximum salary point (£) 19.05 19.05 5.4 
Overheads clinic cost (£) 18.15   
Outpatient tray sterilisation (£) 20   
Total clinic cost (med, min, max) (£) 76.4 (70.7 – 81.65)   
% Staff (median salary point) 50.1%   
% Overheads 23.8%   
% Consumables 26.2%   
Table 6. Total cost of ‘cleft clinic’ per outpatient appointment. Costs and percentage of clinic 
total cost shown for staffing, sterilisation of equipment and overheads. 
 
The clinics associated with the highest mean costs were the ‘audit clinic’ and the ‘joint cleft 
clinic’ which had the most members of staff present. This is shown by the larger staff cost 
percentages of the joint clinic being 62.7% of the total clinic cost (Table 7), and the ‘audit 
clinic’ staff percentage being 82.7% of the total clinic cost (Table 8). The ‘audit clinic’ had 0% 
consumable costs as disposable mirrors and gloves were included in the overheads. 







































Minutes 15 15 15 15 15 15 
Staff cost – minimum 
salary point (£) 
14.1 14.1 4.35 11.25 5.55 5.55 
Staff cost – median salary 
point (£) 
16.65 16.65 4.95 13.5 6.15 6.15 
Staff cost – maximum 
salary point (£) 
19.05 19.05 5.4 15.75 6.75 6.75 
Overheads clinic cost (£) 18.15      
Outpatient tray 
sterilisation (£) 
20      
Total clinic cost (med, min, 
max) (£) 
102.20 (93.05–110.9)      
% Staff (median salary 
point) 
62.7%      
% Overheads 17.8%      
% Consumables 19.6%      
Table 7. Total cost of ‘joint cleft clinic’ per outpatient appointment. Staff present in the 
clinic have been costed, including two members of the SALT team. Costs and percentage of 



































































Minutes 15 15 15 15 15 15 15 15 
Staff cost – minimum 
salary point (£) 14.1 14.1 14.1 11.25 5.55 5.55 5.55 4.35 
Staff cost – median 
salary point (£) 16.65 16.65 16.65 13.5 6.15 6.15 6.15 4.95 
Staff cost – maximum 
salary point (£) 19.05 19.05 19.05 15.75 6.75 6.75 6.75 5.4 
Overheads clinic cost 
(£) 18.15      
  
Outpatient tray 
sterilisation (£) 20      
  
Total clinic cost (med, 
min, max) (£) 
105.00 
(92.70 
– 116.7)   
     
% Staff (median salary 
point) 82.7% 
       
% Overheads 17.3%        
% Consumables 0        
Table 8. Total cost of ‘audit clinic’ per outpatient appointment. Staff present in the clinic 
have been costed, including two members of the SALT team. Costs and percentage of clinic 
total cost shown for staffing, sterilisation of equipment and overheads. 
 
Speech investigation clinics involved five members of staff, of which one was a consultant 
with a significantly higher salary compared with the other members of staff present on the 
clinic. As a result, the staff costs were the highest proportion of the costs (51.2%) as shown 
in Table 9. 



































Minutes 15 15 15 15 15 
Staff cost – 
minimum salary 
point (£) 
14.1 4.35 5.55 5.55 5.55 
Staff cost – median 
salary point (£) 
16.65 4.95 6.15 6.15 6.15 
Staff cost – 
maximum salary 
point (£) 
19.05 5.4 6.75 6.75 6.75 
Overheads clinic 
cost (£) 
18.15     
Outpatient tray 
sterilisation (£) 
20     
Total clinic cost 
(med, min, max) (£) 
 
78.2(73.25– 82.85)     
% Staff (median 
salary point) 
51.2%     
% Overheads 23.2%     
% Consumables 25.6%     
Table 9. Total cost of ‘Speech investigation (SPIN)’ per outpatient appointment. Staff 
present in the clinic have been costed, including two members of the SALT team. Costs and 
percentage of clinic total cost shown for staffing, sterilisation of equipment and overheads. 
 
Cleft nurses play a pivotal role in the delivery of care to cleft affected individuals. This 
involves making initial contact with the parents at a prenatal stage and when the child is 
first born. Cleft nurses carry out face to face (Table 10), telephone reviews (Table 11), and 
home visits (Table 12). Face to face reviews costed more in consumables (46.4% of total 
clinic cost) than telephone reviews or home visits as clinical kits were used which required 
sterilisation. As a result, overheads carry a larger weighting in clinics with no consumable 
costs present and form the larger proportion of the costs (78.6%) in both the home visit and 
phone reviews. Home visits did not include travel costs because patients were living 
different distances away from the hub and this aspect would reduce the generalisability of 
the study.  
 
 
Cleft Nurse Review 
Staff present Specialist Nurse 
Minutes 15 
Staff cost – minimum salary point (£) 4.35 
Staff cost – median salary point (£) 4.95 
Staff cost – maximum salary point (£) 5.4 
Overheads clinic cost (£) 18.15 
Outpatient tray sterilisation (£) 20 
Total clinic cost (med, min, max) (£) 
 
43.1 (42.5 – 43.55) 
% Staff (median salary point) 11.5% 
% Overheads 42.1% 
% Consumables 46.4% 
Table 10. Total cost of ‘Cleft nurse review’ per outpatient appointment. Costs and 





Cleft Nurse Phone Review 
Staff present Specialist Nurse 
Minutes 10 
Staff cost – minimum salary point (£) 2.9 
Staff cost – median salary point (£) 3.3 
Staff cost – maximum salary point (£) 3.6 
Overheads clinic cost (£) 12.1 
Total clinic cost (med, min, max) (£) 15.40 (15 – 15.7) 
% Staff (median salary point) 21.4% 
% Overheads 78.6% 
% Consumables 0.0% 
Table 11. Total cost of ‘Cleft nurse phone review’ per outpatient appointment. Costs and 
percentage of clinic total cost shown for staffing and overheads. Costs and percentage of 
clinic total cost shown for staffing and overheads. 
 
Cleft Nurse Home Visit 
Staff present Specialist Nurse 
Minutes 60 
Staff cost – minimum salary point (£) 17.4 
Staff cost – median salary point (£) 19.8 
Staff cost – maximum salary point (£) 21.6 
Overheads clinic cost (£) 72.6 
Total clinic cost (med, min, max) (£) 92.40 (90 – 94.20) 
% Staff (median salary point) 21.4% 
% Overheads 78.6% 
% Consumables 0.0% 
Table 12. Total cost of ‘Cleft nurse home visit’ per outpatient appointment. This does not 
include travel costs. Costs and percentage of clinic total cost shown for staffing and 
overheads. 
 
Some patients were found to have numerous dental appointments with one BCLP case 
having 20 attended and 12 missed dental appointments, at a total cost of £2336 calculated 
using the median point of the salary scale. The median salary point was used because it was 
the midpoint between the highest and lowest salaries of staff of the same specialty as not 
all staff would be the most junior or the most senior. The largest cost component for this 
clinic (Table 13) was staffing at 39.5%, followed by overheads then consumable costs. Nine 
of the studied case notes had no dental appointments recorded. This reason for these data 
being zero appointments was that treatment may have been carried out in the community 
setting. The community data required was unobtainable for three reasons.  First, the 
timeline for the project, second data protection guidance and third no ethical approval to 
obtain this information. 
Paediatric Dentistry 
Staff present Paediatric Dental Consultant Dental Nurse 
Minutes 20 20 
Staff cost – minimum salary 
point (£) 18.8 5.8 
Staff cost – median salary 
point (£) 22.2 6.6 
Staff cost – maximum salary 
point (£) 25.4 7.2 
Overheads clinic cost (£) 24.2  
Outpatient tray sterilisation 
(£) 
20  
Total clinic cost (med, min, 
max) (£) 
73 (68.8 – 76.8)  
% Staff (median salary 
point) 39.5% 
 
% Overheads 33.2%  
% Consumables 27.4%  
Table 13. Total cost of ‘paediatric dentistry’ per outpatient appointment. This does not 
include specific dental consumables e.g. restorative materials etc. Costs and percentage of 
clinic total cost shown for staffing, sterilisation of equipment and overheads. 
 
Audiology costs were costed per clinic (Table 14). The majority of costs for Audiology clinics 
were consumables for sterilisation of equipment (40.6%). These clinics may involve 
laboratory fees other than the micro costed consumables costs, for hearing aid provision, 
hearing tests or other clinical activity. These additional costs were not measured.  The notes 
were often difficult to interpret or were incomplete, and so a flat rate was costed for 
audiology clinics in order to prevent over costing. It is important to note that these costs can 
be substantial, with a study finding that the cost of a hearing test and provision of a hearing 
aid for one ear was £294, whilst provision of hearing aids for both ears totalled £388 
(Campbell, 2015). In a study reviewing the hearing loss found in patients with cleft palate, it 
was noted that surgical (grommets) or conservative management (hearing aids) were both 
used to treat the hearing loss as a result of otitis media. However, hearing aids were the less 
frequently used method of treatment in 10.1% of cases (Gani et al., 2012). A number of the 










Staff present Audiologist Nurse 
Minutes 15 15 
Staff cost – minimum salary 
point (£) 5.55 4.35 
Staff cost – median salary 
point (£) 6.15 4.95 
Staff cost – maximum salary 
point (£) 6.75 5.4 
Overheads clinic cost (£) 18.15  
Outpatient tray sterilisation 
(£) 20  
Total clinic cost (med, min, 
max) (£) 
49.25 (48.05 – 50.30)  
% Staff (median salary 
point) 22.5% 
 
% Overheads 36.9%  
% Consumables 40.6%  
Table 14. Total cost of ‘audiology’ per outpatient appointment. This does not include 
specific treatment costs e.g. provision of hearing aids etc. Costs and percentage of clinic 
total cost shown for staffing and overheads. 
 
The ‘SALT review’ appointment (Table 15), which is a face to face appointment was the most 
frequently attended overall. This had a (median salary point) clinic cost of £48.60. There 
were no overheads associated with this outpatient clinic and the overheads therefore 
contribute to 74.7% of the overall clinic cost. Staffing of this contributed to a smaller 
percentage of the total clinic cost at 25.3%, as there was only one member of staff present. 
This is the same breakdown of costs as a percentage of the telephone review (Table 16), 
group therapy (Table 17) or the school visits (Table 18). This was because the staff and 
overhead proportions were the same. 
 SALT face to face 
Staff present SALT 
Minutes 30 
Staff cost - min 11.1 
Staff cost - med 12.3 
Staff cost - max 13.5 
Overheads clinic cost (£) 36.3 
Total clinic cost (med, min, max) (£) 48.6 (47.40 – 49.80) 
% Staff (median salary point) 25.3% 
% Overheads 74.7% 
% Consumables 0.0% 
Table 15. Total cost per ‘SALT face to face’ outpatient appointment. Costs and percentage of 
clinic total cost shown for staffing and overheads. 
 
SALT telephone 
Staff present SALT 
Minutes 15 
Staff cost - min 5.55 
Staff cost - med 6.15 
Staff cost - max 6.75 
Overheads clinic cost (£) 18.15 
Total clinic cost (med, min, max) (£) 24.3 (23.70 – 24.90) 
% Staff (median salary point) 25.3% 
% Overheads 74.7% 
% Consumables 0.0% 
Table 16. Total cost of ‘SALT telephone review’ appointments per episode. Costs and 





SALT group therapy. Four children in a group - priced per child 
Staff present SALT 
Minutes 60 
Staff cost - min 22.2 
Staff cost - med 24.6 
Staff cost - max 27 
Overheads clinic cost (£) 18.15 
Total clinic cost (med, min, max) (£) 24.3 (23.70 – 24.90) 
% Staff (median salary point) 25.3% 
% Overheads 74.7% 
% Consumables 0.0% 
Table 17. Total cost of ‘SALT group therapy’ per appointment. As four children are in the 
group, this cost is for 1 child. Costs and percentage of clinic total cost shown for staffing and 
overheads. 
 
SALT school visit or home 
Staff present SALT 
Minutes 60 
Staff cost - min 22.2 
Staff cost - med 24.6 
Staff cost - max 27 
Overheads clinic cost (£) 72.6 
Total clinic cost (med, min, max) (£) 97.2 (94.80 – 99.60) 
% Staff (median salary point) 25.3% 
% Overheads 74.7% 
% Consumables 0.0% 
Table 18. Total cost of ‘SALT school or home visit’ per episode. This does not include travel 




SALT and Psychology 
Staff present SALT Psychologist 
Minutes 30 30 
Staff cost – minimum salary 
point (£) 16.2 22.5 
Staff cost – median salary 
point (£) 21.3 27 
Staff cost – maximum salary 
point (£) 26.4 31.5 
Overheads clinic cost (£) 36.3  
Total clinic cost (med, min, 
max) (£) 
84.60 (75 – 94.20)  
% Staff (median salary 
point) 57.1% 
 
% Overheads 42.9%  
% Consumables 0.0%  
Table 19. Total cost per ‘SALT & Psychology’ joint clinic appointment. This does not include 
travel costs and is costed for a SALT consultant and a psychology consultant. Costs and 
percentage of clinic total cost shown for staffing and overheads. 
 
Photography outpatient (and inpatient) activity was rarely recorded in the notes. Eight 
episodes of photographs were noted in four sets of case notes which were taken in audit 
clinics. If photographs were not seen in each of the clinical notes, they were not micro 
costed. Guidelines from the Institute of Medical Illustrators (Jones and Volcano, 2018) 
suggest that photographs for cleft individuals should be taken as a minimum at the first 
clinic attended and at the 5 years and 10 years audit clinics. These costs have not been 
added to the micro costing for each patient unless specifically noted as they were not 
evidenced. The cost of this appointment was predominantly the overheads cost at 74.7% of 
the clinic cost (Table 20). 
 
Photography 
Staff present Medical illustrator 
Minutes 15 
Staff cost - min 5.55 
Staff cost - med 6.15 
Staff cost - max 6.75 
Overheads clinic cost (£) 18.15 
Total clinic cost (med, min, max) (£) 24.30 (23.70 – 24.90) 
% Staff (median salary point) 25.3% 
% Overheads 74.7% 
% Consumables 0.0% 
Table 20. Total cost per ‘Photography’ appointment. Costs and percentage of clinic total 
cost shown for staffing and overheads. Costs and percentage of clinic total cost shown for 
staffing and overheads. 
 
The costs of psychology input were found to be low across all three phenotypes. These 
clinics involved no consumable costs as staffing and overheads costs made up the costs 
involved with this clinic (Table 21).  Psychology costs were accounted for in some outpatient 
multidisciplinary team clinics. These clinics included the joint cleft clinic, audit clinic and the 
joint psychology & SALT clinics. Patients or their parents may require psychological help 
during the provision of cleft care and this is often provided in the community setting. 
Community records would have required additional ethical approval being granted to access 
parents’ medical records and these have therefore not been costed. Only 12 single specialty 





Staff present Psychologist 
Minutes 30 
Staff cost - min 22.5 
Staff cost - med 27 
Staff cost - max 31.5 
Overheads clinic cost (£) 36.3 
Total clinic cost (med, min, max) (£) 63.30 (58.80 – 67.80) 
% Staff (median salary point) 42.7% 
% Overheads 57.3% 
% Consumables 0.0% 
Table 21. Total cost of ‘Psychology’ appointments per outpatient appointment in the 
hospital setting. Costs and percentage of clinic total cost shown for staffing and overheads. 
 
The costs for outpatients can be divided in accordance with each specialty outpatient clinic 
as shown in Figure 10. This is a total costs plot for each of the three phenotypes (BCLP, CPO 
and UCLP). The three groups had a varied number of patients in each of the groups and so 
the values are not comparable by cost value.  The trends are however comparable. Figure 
10 demonstrates that SALT was the highest outpatient expenditure for BCLP and CPO and 
the second highest expenditure in UCLP. SALT outpatient appointments include SALT home, 
group, face to face and telephone appointments. SALT & Psychology appointments have 
been categorised under the psychology grouping as psychology contributed to the bulk of 
this clinic staffing cost (Table 19). Cleft outpatient clinics were the second highest outpatient 
expenditure for BCLP and CPO respectively and the highest in UCLP. This included audit 
clinics, joint clinics and cleft clinics. It did not include cleft nurse reviews, which have been 
categorised separately as they are a substantial standalone cost. Orthodontic, psychology, 
photography and ENT clinic expenditure were noted as minimal in all groups. 
 
Figure 10. Total outpatient cost for each of the three phenotypes (B=BCLP, C=CPO, U=UCLP) 
split by cost for each specialty.   
5.4 Missed appointments 
 
Costs for missed appointments per phenotype are shown as a percentage on pie charts 
(Figures 11 - 13). The missed appointments as a percentage were similar across all groups 
ranging between 5 and 8%. 
In the BCLP group (Figure 11), which comprised 5 patients, there were 25 missed 
appointments. Although this might suggest that on average each patient missed 
appointments, the range of ‘Did Not Attend’ (DNA) per patient was 0 to 14. DNA costs were 
assigned the same cost as a regular appointment. 
 
Figure 11. BCLP missed appointment (DNA) costs as a percent of total costs 
 
For the CPO group (Figure 12), there were a total of 26 missed appointments, with an 
average of 3.25 DNA appointments per patient, ranging from 0-15 missed appointments. 
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For the UCLP group (Figure 13), a total of 20 DNA appointments were found, with an 
average of two missed appointments per treated individual. The range of missed 
appointments was 0-12. 
 
Figure 13. UCLP missed appointment (DNA) costs as a percent of total costs  
 
5.5 Summary of results 
 
The results show that mean costs for BCLP, CPO and UCLP were £17,004.09 (SD £7,361.83), 
costs £6,137.49 (SD £2,319.87) and £11,619.74 (SD £2,547.81) respectively. Costs in BCLP 
were the highest due to the increased surgical care required when compared with CPO and 
UCLP. CPO had the lowest mean cost due to the least surgical care required. DNA rates were 
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This was a specific study of individuals born with cleft lip and/or palate between the ages of 
birth and 10 years old in cases with no evidence of associated syndromes. It is important to 
note that where patients have syndromes, costs may increase significantly due to 
differences in management. These differences, for example in cases with Pierre Robin 
sequence, can involve difficult airway management and may require the provision of a high 
dependency or a paediatric intensive care unit bed. This may require additional hospital 
review prior to discharge. Such cases may also take additional anaesthetist time to intubate 
and to manage the airway (Oxford handbook of clinical skills for children’s and young 
people’s nursing, 2012), and as a consequence would involve increased costs. 
Some patients were seen in ‘spoke’ hospitals with consultants travelling from the ‘hub’ to 
pocket geographical areas. Travel costs have not been included in calculations due to 
difficulties in being able to accurately ascertain which staff were present in each clinic and 
individual variations of transport modality. Omission of this enables study generalisable to 
other departments by not factoring in travel costs at all. 
One of the main advantages of this study is that the costs were calculated for the separate 
outpatient and inpatient/surgical aspects of cleft care for each phenotype. Thus, each 
dataset could be used to improve each aspect of the care pathway separately. 
 
 
6.2 Participant cohorts 
 
This study follows on from the work of Souster (2017) who carried out a similar micro 
costing of cleft care in UCLP between birth and 5 years of age. Although both his and the 
current study have found that costs were lower than NHS tariff, Souster only considered one 
phenotype, namely UCLP and recommended further work in this field. Recommendations 
for further work included extending the micro costing exercise to CPO and BCLP, ranging 
from birth to 20 years old. As a result, the current study, on three phenotypes from birth to 
10 years of age, was planned and run with a simultaneous parallel micro costing study 
(Durman 2020 – not published at time of writing) of the same 3 phenotypes (UCLP, BCLP 
and CPO), but covering the ages 10 to 20 years of age on a different cohort of patients. The 
cut-off point of this study is up to but not including the ‘10-year audit clinic,’ whilst Durman 
(2020) begins the study from the ’10-year audit clinic.’ The strength of running these two 
parallel studies on the same phenotypes but different cohorts, is that the data from both 
were from patients treated post the 1998 CSAG recommendations in the same centralised 
centre. This allowed the research data to be more comparable to other national data and 
covered the whole of the period an individual with a cleft will likely be in treatment, namely 
birth to 20 years of age.  
In 1998, the CSAG report (Sandy et al., 1998) found that cleft outcomes were worse where 
operators were carrying out procedures infrequently. Recommendations from this report 
included forming a more centralised service. This centralised service involved a hub and 
spoke model in order to ensure that an adequate caseload was being seen by the fewer 
members of the team to aim for better outcomes due to each individual gaining more 
experience in the management of these types of cases. The changes from the CSAG report 
took a number of years to implement due to the significant structural changes to the 
system. Our decision to accept patients as close to 10 years old when recruited for this 
study ensured that the structural changes to the service had been implemented and 
therefore our data is comparable nationally. 
This study was originally planned to include 30 patients, with 10 individuals of each of the 
three phenotype groups. Patients were selected if they met both the inclusion and exclusion 
criteria. Although only 23 sets of case notes were eventually assessed, due to these strict 
inclusion and exclusion criteria, it was felt that this is far outweighed by the advantage of 
having more contemporary research data that can be used to compare cleft data nationally 
and for future research if required. The numbers of studied cases for each of the 
phenotypes is shown in the table below (Table 22). All patients were aged 10 between 2015 
and 2018.  











6.3 Are the costs reasonable? 
 
Prior to this study, there has been no research conducted to micro-cost the provision of 
cleft care within the UK from birth to 10 years old. There has been unpublished work which 
costed the pathway of UCLP from birth to five years of age by Souster (2017). This 
unpublished work was carried out in the same hospital studied here and found an average 
cost for treatment of UCLP to be £7076 per child for the first 5 years of care. For the first 5 
years of treatment on the flowchart below (Figure 14), the mean micro costing of treatment 
can be seen to be £4,695.32, up to the 5-year audit clinic. However, this is a simplified care 
pathway and alongside this would be numerous other appointments with all of the other 
specialties individually, both in the hospital and community setting.  
The current study has shown that the mean cost of provision of care for BCLP from birth to 
10 years of age is £17,004.09 (SD £7,361.83), CPO is £6,137.49 (SD £2,319.87) and UCLP 
£11,619.74 (SD £2,547.81). 
One of the reasons for large standard deviations of costs may be related to the variance in 
the amount of community care provided for some individuals, and that the micro costing 
study only accessed hospital records. A cleft affected child may require more or less input 
from the hospital service depending on the level of community care that is available, and 
they can access. This is an important point to note as some services, such as audiology and 
routine dental care, are often carried out in the community setting for the bulk of the 
population. Some patients may opt to have these aspects of care provided in the 
community for geographical convenience or for personal preference. However, if this is not 
possible, or the treatment or its management is slightly more complex, the patient may be 
assigned to have it provided within the hospital setting. The varying numbers of hospital 
outpatient appointments and the unknown number of outpatient appointment in the 
community setting were not costed and may therefore contribute to the wide range of 
costs.  Only the hospital appointments were micro costed in this study. This might account 
for why some patients appeared to have many dental appointments, when others appeared 
to have very few or indeed none.    
This wide range of costs makes it difficult to necessarily be able to assign a true mean value 
to the costs of BCLP, not only due to the reduced number of case notes assessed for this 
phenotype, which can mean outliers have a large effect, but also because the treatments 
were not costed within the community setting. A larger sample size would help to narrow 
the true mean costs, as would the ability to cost the community-based treatments.  
The mean micro costed values have been applied to the care pathway to help visualise what 




Figure 14. Simplified version of typical cleft care pathway of the 3 cleft phenotypes between 
ages of birth and 10 years old with mean calculated costings applied. Modified from South 
Wales South West Managed Clinical Network – Typical Patient Journey flowcharts (2016) 
6.4 Comparisons to other studies 
 
When costings from this study are compared to other studies, then there are differences, 
but it is important to note where these differences lie. A study which estimated national 
averages of revision surgeries for orofacial clefts in the United States of America (USA) has 
shown that the mean cost per hospitalisation ranged from $7564 (£6018) to $8393 (£6678) 
from the cost year of 2009 (Thompson et al., 2017) (Currency conversion at rate of 0.80 GBP 
to 1 USD on 19/07/2020). These costs when inflated using Bank of England inflation 
calculator were £7930 to £8799. A similar surgery cost found from the collected data would 
range from £1565.17 (palate re repair mean cost) to £1837.05 (lip re repair cost). These 
differences can be attributed to differences in staffing numbers and staff salaries in different 
countries. Funding is also different in other parts of the world, with the USA being a more 
insurance led model. This is an important point as the study goes on to note that there is a 
1.71 odds ratio (95% CI: 1.41—2.09) of the patient having revision surgery of the lip if the 
patient has insurance. It was noted that results were similar for the palate too. This is higher 
than the odds ratio of a syndromic diagnosis requiring revision surgery of the lip (OR 1.47, 
95% CI: 1.16-1.87). In the data found from our study, revision surgeries were not as 
common as described in this study from the USA, most probably as the NHS is a publicly 
funded healthcare system, where money is less likely to be a part of the decision whether or 
not to consider a surgical revision. Instead, any such decision is more clinically driven. 
Kumar et al. (2006) carried out a study in the South West of England which micro costed 
orthognathic surgery and the components within the treatment pathway. This included joint 
orthodontic maxillofacial surgery outpatient clinics being costed at a total of 160 Euros 
(£146, inflated cost using Bank of England inflation calculator £237) (conversion rate on 
19/07/2020 at £0.91/1 Euro). This is comparable to the joint cleft outpatient clinic where 
the cost was found to be £102.20 (£93.05 to £110.90 from the lowest to the highest salary 
points). The additional costs in the joint clinic in the orthognathic surgery study are 
attributed to having more trainees or additional consultants attending rather than SALT and 
psychology team members or geographical differences in hospital costs. The study for 
orthognathic surgery costed the total inpatient and surgery costs for the procedure at 
3327.06 Euros (£3026, inflated cost using Bank of England inflation calculator £4916) 
(conversion rate on 19/07/2020 at £0.91/1 Euro) (Kumar et al., 2006), which is comparable 
to the cost found for ABG surgery in the UCLP and BCLP groups studied here (£2,824.30). 
The study for orthognathic surgery also included provision of high dependency beds where 
required, which would have increased the costs significantly. High dependency and 
paediatric intensive care bed costs have not been factored in this cleft care study as the 
studied case notes showed that none of the patients required this level of care. If this was 
required, it would add to the surgical costs significantly. Interestingly, the study also noted 
that the surgical costs could vary between units, with a range of 5312.26 Euros to 7798.50 
Euros (£4832 to £7093, inflated cost using Bank of England inflation calculator £7851 to 
£11524) (conversion rate on 19/07/2020 at £0.91/1 Euro) (Kumar et al., 2006). This might 
suggest that the costs found here for cleft care surgery appear to be a reasonable 
representation of the patient costs incurred. 
Complications during surgery are risks that apply to all surgical procedures. Surgical 
complications can increase operating time and may indicate the need for revision surgery to 
improve function, aesthetics and/or additional outpatient care provision. Revision surgery in 
this study had a mean cost of £1,837.05 and £1,565.17 for lip revision and palate re-repair 
respectively. Complications also result in an increased hospital length of stay in a study from 
the USA on cleft affected individuals (Nguyen et al., 2014). From the data collected in the 
present study it was seen that for each extra hospital day of stay there is an added cost of 
£286.34 and so additional days can increase the costs significantly. These costs would be 
higher should this bed be required to have high dependency care provision. High 
dependency care or intensive care provision is a consideration in cleft affected individuals, 
but tends to be in cases where there may be potential airway management risk. These risks 
are present in some syndromic cases such as Pierre Robin (Oxford Handbook of Clinical Skills 
for Children’s and Young People’s Nursing, 2012). 
Team familiarity can play a role in efficiency. If a team has a set way of working over a 
number of years, through audit, teaching and open discussions, efficiency can improve and 
may be evidenced by decreased surgical time. This has been shown in other medical surgical 
fields.  In a study of laparoscopic surgery with 100 cases treated by either a familiar certified 
surgical assistant (CSA) or a new CSA in the USA the less experienced operator 
demonstrated much longer associated operative times. It also went on to state “despite 
confinement to a single surgeon and procedure, these results suggest what all surgeons 
know: excellent help is priceless” (Finnesgard et al., 2018). This is important to note, as a 
replacement of any member of the team may risk increasing surgical times, and can explain 
why there can be a large range of times seen in these surgeries, and operating times may 
vary from operator to operator. 
An issue with micro costing is that quality of care is not necessarily measured as there is no 
numerical cost to directly assign for this, nor can it be identified from the clinical notes. 
However, although revision surgery was common it may not necessarily be associated with 
poor quality treatment. Some revision surgery may take place when the individual’s soft 
tissues have matured, or when patients reach puberty and aesthetics may be of more 
concern to them. Outcomes of surgery in this study were not assessed for aesthetics and 
function and so quality is a factor that was not assessed. Should cost-effectiveness be 
investigated, quality of care would need to be taken into account. 
 
Overheads costs for outpatient clinics were assumed to include personal protective 
equipment (PPE) costs. This was a consumable cost included in the overheads for the clinics. 
These costs were nominal due to the low cost of these products and the large volumes in 
which they are purchased. To prevent over costing this was omitted from being additional 
to the clinical overheads. The latter were costed prior to the new guidelines which now exist 
because of COVID-19. These guidelines, which are ever changing, but at the time of writing 
included the need to use facemasks in all hospital areas with enhanced equipment required 
if there was an increased risk identified. Costs of masks, gloves and aprons have increased 
significantly (varying from suppliers), and in future studies these costs would need to carry a 
higher weighting to factor the increased costs. By way of illustration, suitable disposable 
masks (N95) now cost $1.50 (£1.20) each, which is a significant increase from the masks 
previously used which cost less than five pence each (Mick and Murphy., 2020). Overhead 
costs for sterilisation of equipment for outpatient appointments were costed at £20, a cost 
provided by the central sterilisation services at the UHBW. This is a reasonable cost when 
compared to other departments, as found in University Hospitals Birmingham freedom of 
information requests document in 2015 (University Hospitals Birmingham, 2015). 
The majority of cleft affected individuals have some psychological input in joint clinics, but 
rarely go on to need further treatment. The CRANE report of 2018 (CRANE, 2018) showed 
that only 10% of the cleft affected individuals assessed required more treatment with a 
psychologist other than initial consultations in joint cleft clinics. This corroborates with 
found data, as minimal psychological input was found from the clinical notes.  
 
6.5 Data collection   
 
Data was collected from 23 sets of case notes (5 BCLP; 8 CPO; 10 UCLP). The reason for this 
were insufficient records being present. Following the CSAG report, cleft treatment in the 
UK underwent major reorganisation in order to create a centralised service with the aim to 
improve patient outcomes. In order to ensure that the records identified were of children 
who had been through the new centralised system, patients were selected between 2015 
and 2018 where case notes were available.  
Studies involving data collection from hospital notes are known to struggle with data 
extraction. Burnett et al. (2011) found that in 15% of 1,161 cases studied, key outpatient 
clinical information was missing from consultations. The study was based in three London 
teaching hospitals and went on to discuss that having an electronic medical record would 
reduce the incidence of missing clinical information, and concluded that regular auditing 
would also reduce the prevalence of missing information. This is a problem in other 
countries too, as highlighted by a study in the USA where 13.6% of clinicians reported there 
was missing data from 1614 patient notes assessed. This included missing letters, laboratory 
results, history and examination notes and medications for the patient (Smith et al., 2005). 
Ideally, a digital centralised system would improve access to patient data. There is a national 
drive towards digital note keeping throughout the NHS, but previous attempts to do this has 
cost billions of pounds and failed (House of Commons Committee of Public Accounts, 2011). 
A centralised system would allow easier and more comprehensive access to case notes, as 
well as remote access to the data. For the purposes of this retrospective study, the data 
collection involved accessing and assessing:  
- General clinical notes,  
- SALT notes,  
- ENT notes from St Michael’s hospital, 
- Digital notes checked where possible to cross reference with letters sent to ensure 
no clinics were missed.  
In future, a digital note keeping system should allow a more robust data collection process. 
Another more robust way of collecting accurate data would be to carry this project out 
prospectively, using a customised data collection sheet with drop down lists in order to ease 
input and subsequent data analysis. Electronic data collection has been shown to be easier 
to execute and to analyse, but with these benefits come other caveats such as specific 
equipment required and security of devices (Dickinson et al., 2019). Despite the limitations 
with the non-centralised and non-digital infrastructure, every effort was made to ensure 
that a comprehensive dataset was compiled. By cross referencing the data sets, all data that 
could have been found were extracted and assessed to ensure there was no duplication was 
present. This involved considerable time and effort to ensure the data were an accurate 
representation of information from the clinical notes. 
6.5.1 Inpatient data collection 
 
There was a wide range in the time taken for surgery, which affected the observed costs, 
and in order to better understand this, discussions were had with a cleft orthodontic 
consultant. The possible reasons for these variations were considered to be: operator 
variability, difficulty of anaesthesia, complications during the surgery and differences in case 
complexity.  
Different operators may use different techniques, which may vary in the time taken to carry 
out the treatment, in turn adding a range of costs. Experience of the surgeon will also affect 
the time taken to carry out a procedure. This was highlighted by a study which reviewed a 
number of other medical specialty operations including coronary artery bypass grafting 
surgery, knee replacements and bilateral reduction mammoplasties in a tertiary care 
academic hospital in the USA. The study reported that there was a significant reduction in 
operating times associated with surgeon experience. It went on to show that after 15 years 
of experience, surgical times decreased by 8% to 48% depending on the specific procedure 
(Maruthappu et al., 2015). 
Anaesthetic medication is administered by the anaesthetist with the assistance of the 
anaesthetic nurse and often an anaesthetic trainee. Cases of cleft surgery may be a 
particularly important training experience, as it is likely that it may be one of a small number 
of such cases the trainee will see during their training. This may increase the time taken for 
surgeries on cleft affected individuals and this added time has its own associated costs. 
 
Initially when data were collected, data were extracted from the notes. Every attempt was 
made to make the data as accurate as possible. Data were collected retrospectively, and in 
some cases not all surgical or inpatient data were available. Surgical data were 
predominantly collected from hospital ward records in the case notes and anaesthetic 
charts. The latter record the time that anaesthetic medication is given until the end of the 
operation. Recovery time is also noted on the anaesthetic chart. This does not cover the 
time taken to write up notes, to have surgical checklists carried out, nor does it include time 
taken to reflect on the case as clinicians often do. This ‘buffer time’ was deemed to be 20 
minutes either side of the surgery when discussed with a number of consultant maxillofacial 
surgeons and oral surgeons. This is supported by a study in a teaching hospital in England 
which found that a median time of 22.5 minutes wait was found either side of 55 observed 
surgeries over 22 operating lists of gynaecology surgery (Saha et al., 2009). With certain 
complex cases, or those where different equipment was used, this may have been an 
underestimate of the time and cost. However, as this could not be found retrospectively it 
was deemed best to be conservative with the estimation. 
Where surgical/inpatient duration data were not available, average times were applied to 
these specific cases. Mean unilateral lip repair times were 127 minutes in BCLP, whilst UCLP 
mean unilateral lip repair times were 126 minutes. Owing to the similar times, a mean 
unilateral lip repair was applied. Differences between phenotypes were minimal, and due to 
limited numbers of BCLP cases, mean times were used. This was the mean substitution 
method for managing missing data (Kang, 2013), in order to utilise the data found and apply 
it to data that were not available. Mean times were calculated for surgeries of each 
classification using data found from all of the other studied cases of the same classification. 
This was deemed as a fair way of giving a mean surgery time for similar cohorts of patients 
with similar operators. No cases were admitted to a high dependency unit or intensive care 
unit. This may have been the case for other treated cases and perhaps having a larger 
sample would have brought these costs into the means. If the surgical stay duration was not 
available then an average hospital duration (derived from averaging other similar surgical 
stays) was added. This was one night for each of the surgeries, and did not vary between 
phenotypes.  
Grommets operation sheets were not found in any of the case notes but were found to have 
been carried out from letters from ENT or audiology. Whenever it was noted that grommets 
were inserted, an assumed cost found from the literature (Evidence Note 22, 2008) was 
applied and was inflated to the costs that would be incurred at the present time using the 
Bank of England calculator for inflation (Bank of England, 2020). The cost estimated from 
literature for grommets was (pre inflated literature cost £853.20) £1192.42 as a day case. 
This was the lowest mean cost of surgery across all the surgeries that were micro costed. 
The figure seems reasonable based on costs of surgery found in our study, of which the next 
lowest cost of surgical input was palate re-repair costing £1565.17 (with a night in the ward 
included at £286.34). 
 
Pharyngoplasty operation was only noted in one set of case notes. A retrospective analysis 
of 300 consecutive patients in Manitoba who presented from 1980–1995 found that 25% of 
cases had a subsequent pharyngoplasty following primary palate repair (Bicknell et al., 
2002). The wider literature suggests that between 15-45% of cases had a pharyngoplasty 
and that the precise anatomical location of the cleft heavily affected the need for this 
operation (Marinnan et al., 1998 and Mackay et al., 1999). Only one pharyngoplasty was 
noted which is not representative of the literature but may be ascribed to surgical operative 
variation from country to country, or skilled SALT teams working with the patients to avoid 
the need for this surgery. Another more likely reason is that the ‘palate re repair’ surgeries 
may have had a pharyngoplasty carried out as part of the procedure. However, as these 
cases were not specifically labelled as a pharyngoplasty, from the data it appears to be an 
uncommon procedure. 
One of the UCLP cases had their surgeries carried out in Wales. The data for time spent 
under anaesthetic and in recovery was not available. However, the number of days spent in 
hospital was available. Funding is different in NHS Wales when compared with NHS England, 
and can vary between Trusts. As a result, the number of days of hospital stay was costed 
using the studied hospital (Bristol Royal Children’s Hospital) costs, applying average times 
found for similar surgeries in this study to provide a fair representation of the costs. A 
further case had treatment carried out in another hospital in England. This case had the 
Bristol Royal Children’s Hospital costs applied to the surgical times and hospital stay 
duration which was a fair cost comparison. 
Surgical consumables were costed using theatre preparation lists for operative procedures. 
These lists were constructed by the theatre staff and the operating consultants locally in 
order to ensure that equipment was ready for when surgery began. Attendance at the 
surgical procedures confirmed that these lists were a true reflection of the equipment 
provided for each of the surgeries observed. Some of the consumables may have a short 
shelf-life but still require an inventory to be held should they be required for procedures. 
The cost for outdated consumables or wastage was not factored in this micro costing 
analysis. 
A list was obtained from the finance department providing details of overheads. This 
included clinical area costs and maintenance of these areas, insurances, equipment, 
training, servicing costs, general staffing and utilities. Initial outlay of expenses for 
equipment are taken into account in these calculations, however this is applicable to the 
hospital generally.  
The mean overall costs for treatment of a cleft affected individual from birth to 10 years of 
age were found to be £17,00.09 (SD £7,361.83), £6,137.49 (SD £2,319.87) and £11,619.74 
(SD £2,547.81) for BCLP, CPO and UCLP respectively. The mean cost of treatment for CPO 
was found to be lower than that of UCLP, which was lower than that of BCLP. This was an 
expected result, as the care pathway for CPO had less surgical input than both UCLP and 
BCLP. The surgical input for UCLP would be expected to be less than BCLP as the initial cleft 
may be less complex or managed in one operation as it is unilateral. Outpatient input for 
these cases can vary considerably and may include input from the community setting.  
6.6 Health resource group (HRG) code comparisons 
 
HRG codes are used for reimbursing the relevant departments associated with the activities 
that have been carried out. There are numerous procedure codes assigned for each 
different procedure or activity, which apply to both inpatient and outpatient activities. Due 
to the vast number of codes present for different procedures, the codes are grouped using a 
grouping tool which form HRG codes. These groupings describe several procedures or 
activities that are deemed to be similar in order to assign a reference cost for each of these 
groupings. The reference costs are based on national averages and are applicable for 
particular cost years in order to find costs for delivering each service. The amounts 
reimbursed vary based on whether the activity was inpatient, outpatient or a day case and is 
affected by age range and comorbidities. The costs found for the inpatient or surgical 
procedures carried out on individuals with orofacial clefting up until the age of 10 years old 
have been compared in Table 26 to the HRG costs of each procedure.  
The HRG costs (NHS Digital – National Reference Costs 2017- 2018 and tariff costs from 
National tariff workbook 2017 - 2018) are higher than the costs found from this micro 
costing study (Table 23 and Table 24). The variability in costs nationally may be due to a 
number of factors including: 
- Operator variation – some operators may be more efficient than others 
- Technique differences 
- Experience of operator 
- Number of other scheduled cases on an operating list 
- Number of staff present including number of trainees and their stage of training 
- Length of hospital stay – each additional night increases the costs significantly 
- Associated comorbidities 
- Age of patient 























Cost of Each 
(Tariff) 
(Multiplied by MFF 
1.084069) 







Lip repair Primary closure of 
cleft lip 
Very Major, Mouth or Throat 
Procedures, 1 year and 
under 
CA82D £5,765  
 
£3,659 (£3,966.61) Unilateral lip repair 
£2,204.85 
Bilateral lip repair 
£2,301.80 
‘lip re repair’ Lip repair revision Revision of primary 
closure of cleft lip 
Major, Mouth or Throat 
Procedures, 18 years and 
under 
CA83C £3,330 £1,502 (£1,628.27) Lip re repair  
£1,837.05 
‘lip re repair’ Adjustment to 
vermilion border of 
lip NEC 
Adjustment to 
vermilion border of 
lip NEC 
Minor, Mouth or Throat 
Procedures, 2 - 18 years 
CA85B £1,732 £721 (£781.61) 
 
Lip re repair  
£1,837.05 
‘palate repair’ Palate repair Primary repair of 
cleft palate 
Very Major, Mouth or Throat 
Procedures, 1 year and 
under 
CA82D £5,765 £3,659 (£3,966.61) Palate re repair 
£1,565.17 
 
‘palate re repair’ Palate re repair Revision of repair 
of cleft palate 
Very Major, Mouth or Throat 
Procedures, 2 - 18 years 
CA82C £5,683 £2,992 (£3,243.53) Palate re repair 
£1,565.17 
 
‘palate re repair’ Other specified 
correction of 
deformity of palate 
Other specified 
correction of 
deformity of palate 
Very Major, Mouth or Throat 
Procedures, 2 - 18 years 
CA82C £5,683 £2,992 (£3,243.53) Palate re repair 
£1,565.17 
 
‘palate re repair’ Unspecified 
correction of 
deformity of palate 
Unspecified 
correction of 
deformity of palate 
Very Major, Mouth or Throat 
Procedures, 2 - 18 years 
CA82C £5,683 £2,992 (£3,243.53) Palate re repair 
£1,565.17 
 
‘palate re repair’ Suture of palate Suture of palate Minor, Mouth or Throat 
Procedures, 2 - 18 years 
CA85B £1,732 £721 (£781.61) Palate re repair 
£1,565.17 
‘palate re repair’ Other specified 
other repair of 
palate 
Other specified 
other repair of 
palate 
Very Major, Mouth or Throat 
Procedures, 2 - 18 years 
CA82C £5,683 £2,992 (£3,243.53) Palate re repair 
£1,565.17 
 
‘palate re repair’, 
‘lip and palate re 
repair’ 
Unspecified other 
repair of palate 
Unspecified other 
repair of palate 
Minor, Mouth or Throat 
Procedures, 2 - 18 years 
CA85B £1,732 £721 (£781.61) 
 
Palate re repair 
£1,565.17 
 
‘Pharyngoplasty’ Pharyngoplasty Plastic repair of 
pharynx NEC 
Complex, Mouth or Throat 
Procedures, 2 - 18 years 
CA81C £4,837  
 
£3,554 (£3,852.78) Pharyngoplasty 
£1,713.88 
‘Pharyngoplasty’ Pharyngoplasty Other specified 
repair of pharynx 
Complex, Mouth or Throat 
Procedures, 2 - 18 years 
CA81C £ 4,837  
 
£3,554 (£3,852.78) Pharyngoplasty 
£1,713.88 
‘Pharyngoplasty’ Pharyngoplasty Unspecified repair 
of pharynx 
Complex, Mouth or Throat 
Procedures, 2 - 18 years 
CA81C £4,837  
 
£3,554 (£3,852.78) Pharyngoplasty 
£1,713.88 
‘ABG’ ABG Augmentation of 
alveolar ridge NEC 
Major dental procedures CD01B £3,892 £960 (£1,040.71) ABG £2,824.30 
‘ABG’ ABG Alveolar bone graft 
to maxilla 
Intermediate MF procedures CA94 £4,137 £1,904 (£2,064.07) ABG £2,824.30 
‘ABG’ ABG Augmentation of 
alveolar ridge using 
auto bone graft 
Major Dental Procedures, 18 
years and under 
CD01B £3,892 £960 (£1,040.71) ABG £2,824.30 
Table 23. HRG costs (NHS Digital – National Reference Costs 2017- 2018 and tariff costs from National tariff workbook 2017 - 2018) for the 
surgical/inpatient care compared to mean costs found from studied cases.  
 
Outpatient Appointment cost of clinic 
@ median 
pay point/ 
Outpatient reference cost Outpatient tariff cost (Multiplied by MFF 1.084069) 
Cleft clinic £76.40 First attendance: £157; Follow up: £129 First attendance: £176 (£190.80); Follow up: £84 (£91.07) 
Joint cleft clinic £102.20 First attendance: £157; Follow up: £129 First attendance: £176 (£190.80); Follow up: £84 (£91.07) 
Audit clinic £105 First attendance: £157; Follow up: £129 First attendance: £176 (£190.80); Follow up: £84 (£91.07) 
Speech investigation clinic £78.20 First attendance: £122; Follow up: £120 First attendance: £149 (£161.53); Follow up: £77 (£83.47) 
Cleft nurse review-in person £43.10 First attendance: £88; Follow up: £97 No tariff cost available 
Cleft nurse phone review £15.40 First attendance: £137; Follow up: £127 No tariff cost available 
Cleft nurse home visit £92.40 First attendance: £88; Follow up: £97 No tariff cost available 
Paediatric dentistry £73 First attendance: £154; Follow up: £145 No tariff cost available 
Audiology £49.25 First attendance: £96; Follow up: £116 No tariff cost available 
SALT (face to face) £48.60 First attendance: £115; Follow up: £100 No tariff cost available 
SALT telephone £24.30 First attendance: £67; Follow up: £53 No tariff cost available 
SALT group therapy £24.30 First attendance: £115; Follow up: £100 No tariff cost available 
SALT school visit £97.20 First attendance: £115; Follow up: £100 No tariff cost available 
SALT and Psychology £84.60 First attendance: £103; Follow up: £313 No tariff cost available 
Photography £24.30 No reference cost available No tariff cost available 
Psychology £63.30 First attendance: £315; Follow up: £298 No tariff cost available 
Table 24. HRG costs (NHS Digital – National Reference Costs 2017- 2018 and tariff costs from National tariff workbook 2017 - 2018) for the 
outpatient secondary care compared to mean costs found from cases. 
 
Reference costs are costs that are based on national averages of historical data and are not 
the values that are provided to the hospital in order to provide the service. Tariff costs are 
the amounts that are provided to the hospital for delivering the specified clinical activity 
after adjustments have been made due to reference costs being three years in arrears when 
produced. As a result, the reference costs, being national averages do not require market 
force factors (MFF) to be applied to the values. The MFF value assigned to University 
Hospital Bristol was 1.084069. This MFF value is a required adjustment to the tariff cost and 
is multiplied by tariff costs in order to compensate for the differences in costs that is found 
in different parts of the country and between the providers of healthcare. Tariff costs are 
also affected by best clinical practice as opposed to just average costings. 
An important point to note is that the HRG codes are not costed differently for individuals 
who present with associated syndromes when below 18 years old. Patients who presented 
with a syndrome were excluded from this study as results may have not been as 
generalisable due to the large variation in syndromes in which clefting is a feature and the 
vast differences in management depending on the syndrome. This may account for the 
reason HRG reference costs were found to be higher than the those determined using 
micro-costing here, as they were based on an average from historical data of patients. Tariff 
costs have been found to be closer to the calculated costs from our study. 
6.7 Changes to practice 
 
This study has shown the mean costs for the provision of care of three cleft phenotypes. The 
costs found for each of the surgical procedures or outpatient activities could be used as a 
benchmark of costs when commissioning the cleft service. The study also highlights that 
surgical costs make up a larger proportion of the costs than outpatient activity. The results 
from this study together with a parallel study by Durman (2020) investigating similar costs 
for the same phenotypes but between 10-20 years, could be used to develop an evidence 
based protected budget for cleft care provision.  
Another recommendation for practice would be the development of a centralised clinical 
notes system. This would be useful for audit trails, and to minimise missing data.  It would 
also mean that data could be accessed remotely once the infrastructure is in place. The NHS 
is moving to a minimal paper system, which will not only improve research and audit 















This micro costing analysis has found that the mean (SD) costs from birth to 10 years of age 
for provision of cleft care for each phenotype were: 
- BCLP - £17,004.09 (SD £7,361.83) 
 
- CPO - £6,137.49 (SD £2,319.87)  
 
- UCLP - £11,619.74 (SD £2,547.81) 
 
The main costs were derived from inpatient and surgical care of patients. Revision surgeries 
cost less than the initial surgical procedure, but these were still substantial. An example of 
this was unilateral lip re repair (£1837.05) being only £367.80 less than the initial surgical 
intervention (£2204.85). The surgical procedure with the highest cost was alveolar bone 
graft surgery costing £2,824.30. 
Breakdowns of the micro costing found from this study showed that staff costs formed the 
bulk of the costs of both outpatient appointments and in surgical or inpatient care. 
Pharmaceutical costs were the lowest costs to the care pathway. Outpatient activity made 
up the largest proportion activity, with SALT having the most frequent patient contact. 
When compared with the National Tariffs, costs were lower and this likely to be in part 
attributable to the lack of a mechanism for coding patients with comorbidities under the 
age of 18 years.   
Although the findings of this study may be applied to other centres, costs can vary 
significantly between different Trusts and even more so when comparing with other 
countries.  
7.1 Future studies 
 
Previous work carried out by Souster (2017) identified the need to micro cost the provision 
of care to 10 years old and not just in UCLP but also BCLP and CPO. The current project 
paralleled the study by Durman (2020), who micro-costed the provision of care between 10 
and 20 years of age for the same three phenotypes. Together, these projects will provide a 
micro costing of the provision of care from birth to 20 years old for the three cleft 
phenotypes.  
With the advent of electronic patient records it may be easier for future studies to be run 
prospectively, continuously and in a less labour-intensive way. This will mean that any micro 
costing can remain contemporary and easily accessible almost in real time.  
Micro costing should be considered for the treatment of the most common syndromic cases 
to provide a more embracing average cost for cleft care. This would also bring costs closer 
to the HRG tariffs.  
An interesting follow up study that could be carried out would be to evaluate HRG coded 
costs for a patient with orofacial clefting from birth to 10 years of age and compare this with 
micro costed values. Differences between the two could be further investigated in order to 
develop more accurate codes or costings. The limitations of the study might also be 
mitigated, such as seeking ethical approval could be sought to examine community aspects 
of care as well as the prenatal aspects of the provision of cleft care to the whole family. 
Carrying this study out in other units, or even using costs from finance departments of other 
hospitals could provide a range of costs in which the national costs could be developed for 
the provision of cleft care. If this were extended to Wales and Scotland, it could help with 
budget allocation in these countries too. 
Table 25 highlights both the known and the unknown costs found in this micro costing 
study. A further study might identify more of the unknown costs to provide more accurate 
costings for the provision of cleft care for the specified ages.  
 
Known Costs Unknown Costs 
Birth associated costs e.g. cleft nurse review Pre-natal costs 
Outpatient MDT clinic costs Community audiology, psychology, dental 
Outpatient single specialty clinic costs ENT outpatient data - some notes missing 
Outpatient SALT appointment costs Precise day case grommet costs 
Outpatient audit clinic costs Staff travel costs 
Hospital dental review costs Special tests – radiographs, photography 
Inpatient surgery costs  
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Appendix I: Surgical consumables used in pharyngoplasty 
Item Price (£) Number Total (£) 
cleft set 23.12 1 23.12 
15 blade 0.05 6 0.3 
hypos 0.01 3 0.03 
5ml syringe 0.01 1 0.01 
suction tubing 0.37 1 0.37 
small raytec swabs 2.7 5 13.5 
1.25cm throat pack 0.42 1 0.42 
no 4 size patties 0.54 1 0.54 
black suction 
catheter 0.05 2 0.1 
light handles 0.05 2 0.1 
ent drape pack 3.66 1 3.66 
split sheet 3.08 1 3.08 
bowl pack 1.98 1 1.98 
4/0 vicryl W9067 2.06 1 2.06 
2/0 silk W578 0.07 1 0.07 
gloves 1.4 7 9.8 
gown 1.7 7 11.9 
mask with eye 
protection 2.3 7 16.1 
antiseptic betadene 5.61 1 5.61 
crystal violet ink 0.3 1 0.3 
lignospan 0.39 2 0.78 
bipolar lead 46 1 46 
steristrips 1/2 " 0.03 1 0.03 
yellow paraffin 0.59 1 0.59 
hydrofilm 0.08 1 0.08 
saline 3.13 2 6.26 
sharps box 0.04 2 0.08 
table cover 1.13 2 2.26 
bipolar 30 2 60 
dental syringe 0.01 1 0.01 
    















Appendix II: Surgical consumables used in alveolar bone graft 
Item Price (£) Number Total (£) 
oral tray 23.18 1 23.18 
alveolar tray 6.47 1 6.47 
cleft set 23.12 1 23.12 
orthopaedic tray 22.21 1 22.21 
bone nibbler 1 1 1 
osteotomy tray 18.58 1 18.58 
west retractor hip 1 1 1 
T-bar handle & 
jacobs chuck 4.77 1 4.77 
bowl pack 1.98 1 1.98 
light handles 0.05 2 0.1 
small raytec swabs 2.7 5 13.5 
yanker sucker 0.05 1 0.05 
frasier no9 sucker 2.7 2 5.4 
sharps box 0.04 2 0.08 
biogide 97.2 1 97.2 
fine marker pen 0.03 2 0.06 
4/0 vicryl W9067 2.06 1 2.06 
15 blade 0.05 6 0.3 
ent drape pack 3.66 2 7.32 
split sheet 3.08 2 6.16 
Dental syringe 0.01 2 0.02 
5ml syringe 0.01 1 0.01 
10ml leur lock 
syringe 0.01 2 0.02 
hypos 0.01 3 0.03 
bone wax 1.55 1 1.55 
3/0 vicryl rapide 2.2 2 4.4 
4/0 vicryl W9067 2.06 1 2.06 
Antiseptic betadene 5.61 1 5.61 
bipolar 30 2 60 
bipolar lead 46 2 92 
saline 3.13 2 6.26 
Antiseptic betadene 5.61 1 5.61 
Yellow paraffin 0.59 1 0.59 
lignospan 0.39 3 1.17 
gown 1.7 7 11.9 
mask with eye 
protection 2.3 7 16.1 
suction tubing 0.37 1 0.37 
1.25cm throat pack 0.42 1 0.42 
Steristrips 1/2 " 0.03 1 0.03 
monopolar 1.87 1 1.87 
table cover 1.13 2 2.26 
DBX putty 82.77 1 82.77 
grafton 282 1 282 
0.5mm permcol 288 1 288 
gloves 1.4 7 9.8 
Total cost (£)     1099.59 
Appendix III: Surgical consumables used in cleft palate repair 
Item Price (£) Number Total (£) 
cleft set 23 1 23 
light handles 0 2 0.1 
ent drape pack 4 1 3.7 
15 blade 0 6 0.3 
5ml syringe 0 1 0 
10ml leur lock 
syringe 0 2 0 
retrobulbar needle 0 1 0 
filter needles 0 2 0 
small raytec swabs 3 5 14 
sharps box 0 1 0 
gown 2 7 12 
mask with eye 
protection 2 7 16 
suction tubing 0 1 0.4 
1.25cm throat pack 0 1 0.4 
steristrips 1/2 " 0 1 0 
nasal swabs 1 4 5 
microscope handle 
covers 4 1 3.6 
micro pattie (1/4" x 
1/4" yellow string) 1 1 1.1 
60 degree beaver 
blade 8 1 7.7 
4/0 vicryl W9067 2 1 2.1 
4/0 PDS round 2 1 2.2 
5/0 pds 2 1 2.2 
5/0 vicryl round 2 1 1.7 
4/0 prolene 1 1 1.3 
antiseptic betadene 6 1 5.6 
bipolar 30 2 60 
bipolar lead 46 2 92 
saline 3 2 6.3 
antiseptic betadene 6 1 5.6 
Yellow paraffin 1 1 0.6 
lignospan 0 3 1.2 
crystal violet ink 0 1 0.3 
monopolar 2 1 1.9 
yanker sucker 0 1 0.1 
fine marker pen 0 1 0 
hypos 0 3 0 
dental syringe 0 2 0 
table cover 1 2 2.3 
gloves 1 7 9.8 






Appendix IV: Surgical consumables used in cleft lip repair 
Item Price (£) Number Total (£) 
cleft set 23.12 1 23.12 
light handles 0.05 2 0.1 
suction tubing 0.37 1 0.37 
1.25cm throat pack 0.42 1 0.42 
small raytec swabs 2.7 5 13.5 
sharps box 0.04 1 0.04 
filter needles 0.02 2 0.04 
5ml syringe 0.01 1 0.01 
ophthalmic blade 4.05 1 4.05 
nasal swabs 1.25 8 10 
60 degree beaver 
blade 7.67 1 7.67 
ent drape pack 3.66 1 3.66 
antiseptic betadene 5.61 1 5.61 
bipolar 30 2 60 
bipolar lead 46 2 92 
saline 3.13 2 6.26 
antiseptic betadene 5.61 1 5.61 
yellow paraffin 0.59 1 0.59 
lignospan 0.39 2 0.78 
yankeur sucker 0.05 1 0.05 
fine marker pen 0.03 1 0.03 
steristrips 1/2 " 0.03 1 0.03 
gown 1.7 7 11.9 
mask with eye 
protection 2.3 7 16.1 
hypos 0.01 3 0.03 
dental syringe 0.01 1 0.01 
monopolar 1.87 1 1.87 
6/0 monocryl 
reverse cut 2.2 1 2.2 
7/0 vicryle rapide 2.2 1 2.2 
dermabond 17 1 17 
5/0 vicryl round 1.7 1 1.7 
4/0 PDS round 2.19 1 2.19 
saline 3.13 2 6.26 
bowl pack 1.98 1 1.98 
blue suction 
catheter no. 8 0.05 1 0.05 
table cover 1.13 2 2.26 
15 blade 0.05 6 0.3 
gloves 1.4 7 9.8 








Appendix V: Anaesthetic medications and costs associated used in the surgical procedures 
Anaesthetic medication Cost (£) 
Fentanyl (500mg) 0.80 
Propofol (200mg) 1.50 
Atracurium (50mg) 2.20 
Ondansetron (4mg) 0.12 
Dexamethasone (6.6mg) 2.00 
Co-amoxiclav (1.2g) 0.90 
IV paracetamol (1000mg) 1.20 
Hartmann’s (1 litre) 0.91 
Sevoflurane (/hour) 5.00 
 
 
Appendix IV: ‘To take away’ (TTA) medications and costs 
TTA's  Cost (£) 
Paracetamol (32) 0.73 
Ibuprofen (24) 0.66 
Chlorhexidine (300 ml bottle) 4.09 
Co-amoxiclav 500/125 (21) 1.84 
Total 7.32 
 
 
